<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644619303356</prism:url><dc:identifier>doi:10.1016/j.drudis.2019.08.007</dc:identifier><eid>1-s2.0-S1359644619303356</eid><prism:doi>10.1016/j.drudis.2019.08.007</prism:doi><pii>S1359-6446(19)30335-6</pii><dc:title>Soft drugs for dermatological applications: recent trends </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><prism:volume>24</prism:volume><prism:issueIdentifier>12</prism:issueidentifier><prism:startingPage>2234</prism:startingpage><prism:endingPage>2246</prism:endingpage><prism:pageRange>2234-2246</prism:pagerange><prism:number>12</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2019-12-31</prism:coverdate><prism:coverDisplayDate>December 2019</prism:coverdisplaydate><prism:copyright>© 2019 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Aprile, Silvio</dc:creator><dc:creator>Serafini, Marta</dc:creator><dc:creator>Pirali, Tracey</dc:creator><dc:description>
                  A soft drug (SD) displays a metabolically labile spot and, after having exerted its activity in the site of action, undergoes a fast metabolism, leading to inactive metabolites. The SD approach has recently found widespread application in the dermatological field because it provides a means of localising the therapeutic effect in skin, while minimising systemic exposure. The literature is rapidly growing of successful examples of compounds targeting sphingosine-1-phosphate receptor 1 (S1PR1), transient receptor potential vanilloid 1 (TRPV1), Janus kinase (JAK), caspase 1, and histone deacetylase (HDAC), for the treatment of skin inflammatory, autoimmune, and oncological diseases. As a demonstration of the potential of this strategy, the SD approach recently led to the approval of crisaborole, a soft phosphodiesterase 4 (PDE4) inhibitor, for atopic dermatitis, while other agents are in clinical development.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644619303356" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644619303356" rel="scidir"/></link></coredata><objects><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="142" height="163" size="20813">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="143" height="164" size="18655">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="143" height="164" size="20484">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="82" size="3068">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="7993">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="100" size="4449">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="71" size="2208">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="83" size="2989">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="112" size="4573">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="88" height="101" size="5114">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="88" height="101" size="4052">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="88" height="101" size="4696">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="312" size="39381">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="385" size="76427">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="382" size="54492">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="405" height="131" size="8941">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="315" size="36031">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="428" size="60055">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="393" height="452" size="67406">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="392" height="450" size="37519">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="392" height="450" size="56663">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1383" size="279370">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1705" size="629103">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1690" size="387867">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1793" height="582" size="61744">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1396" size="262591">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1895" size="441589">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644619303356-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85072222405</scopus-id><scopus-eid>2-s2.0-85072222405</scopus-eid><pubmed-id>31494188</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85072222405" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20190905">2019-09-05</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20190905">2019-09-05</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20191130">2019-11-30</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20191130">2019-11-30</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2019-11-30T12:52:39</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644619303356</xocs:eid>
      <xocs:pii-formatted>S1359-6446(19)30335-6</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644619303356</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2019.08.007</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644619X00136</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20191130">2019-11-30T13:50:41.755367Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20191201</xocs:date-search-begin>
      <xocs:date-search-end>20191231</xocs:date-search-end>
      <xocs:year-nav>2019</xocs:year-nav>
      <xocs:indexeddate epoch="1567698682">2019-09-05T15:51:22.149683Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authlast grantnumber grantsponsor highlightsabst primabst pubtype ref teaserabst vitae</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>24</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>24</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>12</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>12</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 24, Issue 12</xocs:vol-iss-suppl-text>
      <xocs:sort-order>6</xocs:sort-order>
      <xocs:first-fp>2234</xocs:first-fp>
      <xocs:last-lp>2246</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>2234</xocs:first-page>
         <xocs:last-page>2246</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>201912</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>December 2019</xocs:cover-date-text>
      <xocs:cover-date-start>2019-12-01</xocs:cover-date-start>
      <xocs:cover-date-end>2019-12-31</xocs:cover-date-end>
      <xocs:cover-date-year>2019</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>REVIEWS</xocs:hub-sec-title>
         <xocs:hub-sec>
            <xocs:hub-sec-title>Keynote</xocs:hub-sec-title>
         </xocs:hub-sec>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2019 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>SOFTDRUGSFORDERMATOLOGICALAPPLICATIONSRECENTTRENDS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>APRILE</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>S</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Softness criteria for topical dermatological drugs</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Considerations of metabolism in SD design</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Tools to assess skin metabolism</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Illustrative examples of dermatological SDs</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Steroids</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Other soft dermatological agents</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>Anticholinergics</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>PDE4 inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>S1PR1 modulators</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>TRPV1 modulators</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>JAK inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>Caspase 1 inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>Androgen antagonists</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>HDAC inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>EGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>229</xocs:ref-first-fp>
            <xocs:ref-last-lp>230</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1977</xocs:ref-pub-year>
            <xocs:ref-first-fp>98</xocs:ref-first-fp>
            <xocs:ref-last-lp>135</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>DESIGNBIOPHARMACEUTICALPROPERTIESTHROUGHPRODRUGSANALOGS</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>NOVELAPPROACHESFORDESIGNMEMBRANETRANSPORTPROPERTIESDRUGS</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1980</xocs:ref-pub-year>
            <xocs:ref-first-fp>469</xocs:ref-first-fp>
            <xocs:ref-last-lp>474</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1980</xocs:ref-pub-year>
            <xocs:ref-first-fp>566</xocs:ref-first-fp>
            <xocs:ref-last-lp>569</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1980</xocs:ref-pub-year>
            <xocs:ref-first-fp>474</xocs:ref-first-fp>
            <xocs:ref-last-lp>480</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1982</xocs:ref-pub-year>
            <xocs:ref-first-fp>989</xocs:ref-first-fp>
            <xocs:ref-last-lp>991</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>HEO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>91</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>58</xocs:ref-first-fp>
            <xocs:ref-last-lp>101</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>123</xocs:ref-first-fp>
            <xocs:ref-last-lp>132</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>BUCHWALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>403</xocs:ref-first-fp>
            <xocs:ref-last-lp>413</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0055">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-last-lp>608</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>BURGERSMEDICINALCHEMISTRYDRUGDISCOVERY</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>RETROMETABOLISMBASEDDRUGDESIGNTARGETING</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0060">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>RETROMETABOLICDRUGDESIGNTARGETING</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0065">
            <xocs:ref-normalized-surname>EILSTEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1681</xocs:ref-first-fp>
            <xocs:ref-last-lp>1694</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0070">
            <xocs:ref-normalized-surname>OESCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2411</xocs:ref-first-fp>
            <xocs:ref-last-lp>2456</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0075">
            <xocs:ref-normalized-surname>VANEIJL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-article-number>e41721</xocs:ref-article-number>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0080">
            <xocs:ref-normalized-surname>OESCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2135</xocs:ref-first-fp>
            <xocs:ref-last-lp>2190</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0085">
            <xocs:ref-normalized-surname>MANEVSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2049</xocs:ref-first-fp>
            <xocs:ref-last-lp>2057</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0090">
            <xocs:ref-normalized-surname>GOTZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>364</xocs:ref-first-fp>
            <xocs:ref-last-lp>369</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0095">
            <xocs:ref-normalized-surname>SHARMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>817</xocs:ref-first-fp>
            <xocs:ref-last-lp>827</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0100">
            <xocs:ref-normalized-surname>TESTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>HYDROLYSISINDRUGPRODRUGMETABOLISMCHEMISTRYBIOCHEMISTRYENZYMOLOGY</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0105">
            <xocs:ref-normalized-surname>SVENSSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>247</xocs:ref-first-fp>
            <xocs:ref-last-lp>253</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0110">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1313</xocs:ref-first-fp>
            <xocs:ref-last-lp>1318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0115">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>532</xocs:ref-first-fp>
            <xocs:ref-last-lp>536</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0120">
            <xocs:ref-normalized-surname>HOSOKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>412</xocs:ref-first-fp>
            <xocs:ref-last-lp>431</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0125">
            <xocs:ref-normalized-surname>BAHAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>3979</xocs:ref-first-fp>
            <xocs:ref-last-lp>3988</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0130">
            <xocs:ref-normalized-surname>SAMIR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>82</xocs:ref-first-fp>
            <xocs:ref-last-lp>89</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0135">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1673</xocs:ref-first-fp>
            <xocs:ref-last-lp>1684</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0140">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>227</xocs:ref-first-fp>
            <xocs:ref-last-lp>235</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0145">
            <xocs:ref-normalized-surname>ROSS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>E5786</xocs:ref-first-fp>
            <xocs:ref-last-lp>E5795</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0150">
            <xocs:ref-normalized-surname>SOWADA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>129</xocs:ref-first-fp>
            <xocs:ref-last-lp>139</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0155">
            <xocs:ref-normalized-surname>BACQUEVILLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>190</xocs:ref-first-fp>
            <xocs:ref-last-lp>201</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0160">
            <xocs:ref-normalized-surname>BATZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>374</xocs:ref-first-fp>
            <xocs:ref-last-lp>835</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0165">
            <xocs:ref-normalized-surname>BUCHWALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>193</xocs:ref-first-fp>
            <xocs:ref-last-lp>208</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0170">
            <xocs:ref-normalized-surname>DRUZGALA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1991</xocs:ref-pub-year>
            <xocs:ref-first-fp>149</xocs:ref-first-fp>
            <xocs:ref-last-lp>154</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0175">
            <xocs:ref-normalized-surname>KURUCZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>83</xocs:ref-first-fp>
            <xocs:ref-last-lp>92</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0180">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>MULTICENTERTRIALFORPATIENTSACUTECROHNSDISEASE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0185">
            <xocs:ref-normalized-surname>ONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1989</xocs:ref-pub-year>
            <xocs:ref-first-fp>1662</xocs:ref-first-fp>
            <xocs:ref-last-lp>1665</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0190">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1745</xocs:ref-first-fp>
            <xocs:ref-last-lp>1753</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0195">
            <xocs:ref-normalized-surname>BIGGADIKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-last-lp>21</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0200">
            <xocs:ref-normalized-surname>PROCOPIOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>602</xocs:ref-first-fp>
            <xocs:ref-last-lp>612</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0205">
            <xocs:ref-normalized-surname>ANGELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>831</xocs:ref-first-fp>
            <xocs:ref-last-lp>839</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0210">
            <xocs:ref-normalized-surname>LAURENT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1975</xocs:ref-pub-year>
            <xocs:ref-first-fp>185</xocs:ref-first-fp>
            <xocs:ref-last-lp>192</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0215">
            <xocs:ref-normalized-surname>OMAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5131</xocs:ref-first-fp>
            <xocs:ref-last-lp>5145</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0220">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>83</xocs:ref-first-fp>
            <xocs:ref-last-lp>89</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0225">
            <xocs:ref-normalized-surname>DOBRICIC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>786</xocs:ref-first-fp>
            <xocs:ref-last-lp>797</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0230">
            <xocs:ref-normalized-surname>LABAREE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>1802</xocs:ref-first-fp>
            <xocs:ref-last-lp>1814</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0235">
            <xocs:ref-normalized-surname>LABAREE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1886</xocs:ref-first-fp>
            <xocs:ref-last-lp>1904</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0240">
            <xocs:ref-normalized-surname>BRUFANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>543</xocs:ref-first-fp>
            <xocs:ref-last-lp>556</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0245">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1681</xocs:ref-first-fp>
            <xocs:ref-last-lp>1689</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0250">
            <xocs:ref-normalized-surname>JI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1427</xocs:ref-first-fp>
            <xocs:ref-last-lp>1435</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0255">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2035</xocs:ref-first-fp>
            <xocs:ref-last-lp>2044</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0260">
            <xocs:ref-normalized-surname>SAMIR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2791</xocs:ref-first-fp>
            <xocs:ref-last-lp>2797</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0265">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ASAFETYSTUDYBBI4000GELINPATIENTSAXILLARYHYPERHIDROSIS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0270">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>SAFETYEFFICACYSTUDYSOFPIRONIUMBROMIDEINSUBJECTSAXILLARYHYPERHIDROSISBBI4000CL301CARDIGANI</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0275">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>SAFETYEFFICACYSTUDYSOFPIRONIUMBROMIDEINSUBJECTSAXILLARYHYPERHIDROSISBBI4000CL302CARDIGANII</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0280">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>21</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0285">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>585</xocs:ref-first-fp>
            <xocs:ref-last-lp>593</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0290">
            <xocs:ref-normalized-surname>AKAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2129</xocs:ref-first-fp>
            <xocs:ref-last-lp>2132</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0295">
            <xocs:ref-normalized-surname>ZANE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>853</xocs:ref-first-fp>
            <xocs:ref-last-lp>866</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0300">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>2270</xocs:ref-first-fp>
            <xocs:ref-last-lp>2274</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0305">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>APHASE2STUDYE6005INPATIENTSATOPICDERMATITIS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0310">
            <xocs:ref-normalized-surname>ISHII</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>105</xocs:ref-first-fp>
            <xocs:ref-last-lp>112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0315">
            <xocs:ref-normalized-surname>OHBA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>241</xocs:ref-first-fp>
            <xocs:ref-last-lp>246</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0320">
            <xocs:ref-normalized-surname>FURUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1403</xocs:ref-first-fp>
            <xocs:ref-last-lp>1408</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0325">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>LEO29102CREAMINTREATMENTATOPICDERMATITIS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0330">
            <xocs:ref-normalized-surname>FELDING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>5893</xocs:ref-first-fp>
            <xocs:ref-last-lp>5903</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0335">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>13</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0340">
            <xocs:ref-normalized-surname>BORODZICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>13</xocs:ref-first-fp>
            <xocs:ref-last-lp>21</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0345">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ACT128800INPATIENTSMODERATESEVERECHRONICPLAQUEPSORIASIS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0350">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ACT128800INPSORIASIS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0355">
            <xocs:ref-normalized-surname>BELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3255</xocs:ref-first-fp>
            <xocs:ref-last-lp>3259</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0360">
            <xocs:ref-normalized-surname>BELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>341</xocs:ref-first-fp>
            <xocs:ref-last-lp>347</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0365">
            <xocs:ref-normalized-surname>BODE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2809</xocs:ref-first-fp>
            <xocs:ref-last-lp>2814</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0370">
            <xocs:ref-normalized-surname>GAVVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>202</xocs:ref-first-fp>
            <xocs:ref-last-lp>210</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0375">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>143</xocs:ref-first-fp>
            <xocs:ref-last-lp>162</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0380">
            <xocs:ref-normalized-surname>SERAFINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4436</xocs:ref-first-fp>
            <xocs:ref-last-lp>4455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0385">
            <xocs:ref-normalized-surname>PIRALI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>207</xocs:ref-first-fp>
            <xocs:ref-last-lp>221</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0390">
            <xocs:ref-normalized-surname>KARGBO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>143</xocs:ref-first-fp>
            <xocs:ref-last-lp>144</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0395">
            <xocs:ref-normalized-surname>DAMSKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>736</xocs:ref-first-fp>
            <xocs:ref-last-lp>744</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0400">
            <xocs:ref-normalized-surname>RITZEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>641</xocs:ref-first-fp>
            <xocs:ref-last-lp>646</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0405">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>APHASE1STUDYEVALUATETOLERABILITYSAFETYPHARMACOKINETICSTOPICALPF06263276INHEALTHYSUBJECTS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0410">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>A12DAYSTUDYEVALUATEATOPICALDRUGTREATPLAQUEPSORIASIS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0415">
            <xocs:ref-normalized-surname>JONES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>767</xocs:ref-first-fp>
            <xocs:ref-last-lp>786</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0420">
            <xocs:ref-normalized-surname>MACKENZIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>568</xocs:ref-first-fp>
            <xocs:ref-last-lp>576</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0425">
            <xocs:ref-normalized-surname>FOURNIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4030</xocs:ref-first-fp>
            <xocs:ref-last-lp>4051</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0430">
            <xocs:ref-normalized-surname>MITCHELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1310</xocs:ref-first-fp>
            <xocs:ref-last-lp>1313</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0435">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>424</xocs:ref-first-fp>
            <xocs:ref-last-lp>442</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0440">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>EFFICACYSAFETYTOLERABILITYSTUDYSHAPEINIAIBIIACUTANEOUSTCELLLYMPHOMA</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0445">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>TOPICALREMETINOSTATINTREATINGPATIENTCUTANEOUSBASALCELLCANCER</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0450">
            <xocs:ref-normalized-surname>CLINICALTRIALSGOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>TOPICALREMETINOSTATGELNEOADJUVANTTHERAPYINPATIENTSSQUAMOUSCELLCARCINOMASCC</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0455">
            <xocs:ref-normalized-surname>BRADNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>800</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0460">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>8525</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0465">
            <xocs:ref-normalized-surname>DUVIC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>7562</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0470">
            <xocs:ref-normalized-surname>FOURNIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2985</xocs:ref-first-fp>
            <xocs:ref-last-lp>2992</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0475">
            <xocs:ref-normalized-surname>PRUSAKIEWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1517</xocs:ref-first-fp>
            <xocs:ref-last-lp>1524</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0480">
            <xocs:ref-normalized-surname>PIRALI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1542</xocs:ref-first-fp>
            <xocs:ref-last-lp>1554</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0485">
            <xocs:ref-normalized-surname>BODOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>569</xocs:ref-first-fp>
            <xocs:ref-last-lp>618</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>COMPUTATIONALMOLECULARBIOLOGY</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>ROLECOMPUTATIONALTECHNIQUESINRETROMETABOLICDRUGDESIGNSTRATEGIES</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0490">
            <xocs:ref-normalized-surname>BUCHWALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>210</xocs:ref-first-fp>
            <xocs:ref-last-lp>217</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0495">
            <xocs:ref-normalized-surname>BUCHWALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>923</xocs:ref-first-fp>
            <xocs:ref-last-lp>933</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0500">
            <xocs:ref-normalized-surname>BOLAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>4309</xocs:ref-first-fp>
            <xocs:ref-last-lp>4324</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>APRILEX2019X2234</xocs:refkey3>
         <xocs:refkey4lp>APRILEX2019X2234X2246</xocs:refkey4lp>
         <xocs:refkey4ai>APRILEX2019X2234XS</xocs:refkey4ai>
         <xocs:refkey5>APRILEX2019X2234X2246XS</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2020-11-30T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2020-11-30T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2019 Elsevier Ltd. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2019-09-12T07:52:06.101Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>AIRC</xocs:funding-agency-acronym>
            <xocs:funding-agency>Associazione Italiana per la Ricerca sul Cancro</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100005010</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/3175395</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency>Fondazione CRT</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100007364</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/3175395</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>MIUR</xocs:funding-agency-acronym>
            <xocs:funding-agency>Ministero dell’Istruzione, dell’Università e della Ricerca</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100003407</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/3175395</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(19)30335-6</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644619303356</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644619303356</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2019.08.007</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2019-11-30T12:59:49.643769Z</xocs:timestamp>
         <xocs:cover-date-start>2019-12-01</xocs:cover-date-start>
         <xocs:cover-date-end>2019-12-31</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/MAIN/application/pdf/a4662ceaf3d353fef406e55040b252a0/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1505846</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>13</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644619303356-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/PREVIEW/image/png/42012b3e82b4e6a5fd89c514150362b4/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>73335</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx1/THUMBNAIL/image/gif/c5af30201cc91c68907bbd5e3af0871c/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>20813</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>142</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx2/THUMBNAIL/image/gif/7f493d72af4083457873ed6f2260947e/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18655</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>143</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx3/THUMBNAIL/image/gif/91a1963a604d3b03f0d3be46822f3496/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>20484</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>143</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr1/THUMBNAIL/image/gif/b15fe76ae37333289d0d27383db26b25/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3068</xocs:filesize>
               <xocs:pixel-height>82</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr2/THUMBNAIL/image/gif/b9dd474a2ea03ad1e08cde79a0e64479/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7993</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr3/THUMBNAIL/image/gif/8c1978faf1a4246e6fdaef3c90bc27cc/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4449</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr4/THUMBNAIL/image/gif/36923893a454212dcae543fa7fcace28/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2208</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr5/THUMBNAIL/image/gif/005641f14b16ea5a696ac8563946c577/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2989</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr6/THUMBNAIL/image/gif/aae6dc28296dd83edce4bbe1df1738a3/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4573</xocs:filesize>
               <xocs:pixel-height>112</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx1/DOWNSAMPLED/image/jpeg/6dbff02f51f06e300ec477876bfe991e/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5114</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>88</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx2/DOWNSAMPLED/image/jpeg/56a29fc635f59035111959bbeabdf190/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4052</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>88</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx3/DOWNSAMPLED/image/jpeg/d15d8b2a15281c96c2ef08e63b7eaab6/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4696</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>88</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr1/DOWNSAMPLED/image/jpeg/b8772b01138b52c3012dce8bfe181e50/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39381</xocs:filesize>
               <xocs:pixel-height>312</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr2/DOWNSAMPLED/image/jpeg/8ee94e7def5732c2a0fe4da45d086d4d/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>76427</xocs:filesize>
               <xocs:pixel-height>385</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr3/DOWNSAMPLED/image/jpeg/88f8709651c5c7ae6badb034a3c9002b/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54492</xocs:filesize>
               <xocs:pixel-height>382</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr4/DOWNSAMPLED/image/jpeg/d3165d6725853f2762d92fd0711ba3a4/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>8941</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>405</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr5/DOWNSAMPLED/image/jpeg/2f25c0d7b0fecbb830e5b5f6eccb287c/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36031</xocs:filesize>
               <xocs:pixel-height>315</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr6/DOWNSAMPLED/image/jpeg/ec5beff0405095b4f591e52392a27985/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60055</xocs:filesize>
               <xocs:pixel-height>428</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx1/HIGHRES/image/jpeg/5ebfad0df130a51050aa090a057504cc/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>67406</xocs:filesize>
               <xocs:pixel-height>452</xocs:pixel-height>
               <xocs:pixel-width>393</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx2/HIGHRES/image/jpeg/401bcaa8c2eda0929ee44ac731369837/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37519</xocs:filesize>
               <xocs:pixel-height>450</xocs:pixel-height>
               <xocs:pixel-width>392</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/fx3/HIGHRES/image/jpeg/e27f03935c13161eb7984d19eb451c45/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56663</xocs:filesize>
               <xocs:pixel-height>450</xocs:pixel-height>
               <xocs:pixel-width>392</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr1/HIGHRES/image/jpeg/a0c62ca433155292713797730865c300/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>279370</xocs:filesize>
               <xocs:pixel-height>1383</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr2/HIGHRES/image/jpeg/b0f891db91524249fd5a3215e67c7172/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>629103</xocs:filesize>
               <xocs:pixel-height>1705</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr3/HIGHRES/image/jpeg/7cc1cf454b544b3e7176ae0835115039/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>387867</xocs:filesize>
               <xocs:pixel-height>1690</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr4/HIGHRES/image/jpeg/a2484c9c685ed0fc3b0d40c68555f1e7/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>61744</xocs:filesize>
               <xocs:pixel-height>582</xocs:pixel-height>
               <xocs:pixel-width>1793</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr5/HIGHRES/image/jpeg/2e395003200d6f349005ebaa29486328/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>262591</xocs:filesize>
               <xocs:pixel-height>1396</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644619303356-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644619303356/gr6/HIGHRES/image/jpeg/7b2fdf00db80d6a29db4ed761c2250e5/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>441589</xocs:filesize>
               <xocs:pixel-height>1895</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.5" xml:lang="en" docsubtype="rev">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>2532</aid>
            <ce:pii>S1359-6446(19)30335-6</ce:pii>
            <ce:doi>10.1016/j.drudis.2019.08.007</ce:doi>
            <ce:copyright type="full-transfer" year="2019">Elsevier Ltd</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spar0005" view="all">Illustrative examples of marketed soft drugs (SDs). Metabolically labile ‘soft spots’ are highlighted in blue.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0135" role="short">Figure 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S1359644619303356/gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spar0010" view="all">Hydrolytic metabolic inactivation of ester soft drugs (SDs): enzymes involved and <ce:italic>in vitro</ce:italic> tools used to assess it. Abbreviations: AChE, acetylcholinesterase; BChE, butyrylcholinesterase; HaCaT, human skin keratinocytes cell line; hCEs, human carboxylesterases; HDL, high-density lipoprotein; HSA, human serum albumin; PON, paraoxonase.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0140" role="short">Figure 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S1359644619303356/gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0015">
               <ce:label>Figure 3</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="spar0015" view="all">Soft steroids: representative examples. Metabolically labile ‘soft spots’ are highlighted in blue.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0145" role="short">Figure 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S1359644619303356/gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0020">
               <ce:label>Figure 4</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="spar0020" view="all">Sofpironium bromide. The metabolically labile ‘soft spot’ is highlighted in blue.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0150" role="short">Figure 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S1359644619303356/gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0025">
               <ce:label>Figure 5</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="spar0025" view="all">Representative soft phosphodiesterase 4 (PDE4) inhibitors. Metabolically labile ‘soft spots’ are highlighted in blue.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0155" role="short">Figure 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S1359644619303356/gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0030">
               <ce:label>Figure 6</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="spar0030" view="all">Other soft dermatological agents. Metabolically labile ‘soft spots’ are highlighted in blue. Abbreviations: HDAC, histone deacetylase; JAK, Janus kinase; S1PR1, sphingosine-1-phosphate receptor 1; TRPV1, transient receptor potential vanilloid 1; UDPGA, uridine diphosphate glucuronic acid.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0160" role="short">Figure 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S1359644619303356/gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0005" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="spar0035" view="all">Available data for the most characterized SDs discussed in the review<ce:cross-ref id="crf0005" refid="tblfn0005">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0165" role="short">Table 1</ce:alt-text>
               <tgroup cols="9">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <colspec colname="col5"/></colspec>
                  <colspec colname="col6"/></colspec>
                  <colspec colname="col7"/></colspec>
                  <colspec colname="col8"/></colspec>
                  <colspec colname="col9"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Class</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase of development<cross-ref id="crf0010" refid="tblfn0010">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Enzymatic reaction</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Activity SD/metabolite</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Model for softness assessment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clearance</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Experimental<cross-ref id="crf0015" refid="tblfn0015">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="3" role="rowhead rowgroup">
                           <bold>9</bold>, LE; <bold>10</bold>, ED</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="3" role="rowhead">Steroids</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="3">LE: approved ED: clinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="3">Hydrolysis (LE and ED)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="3">LE: K<inf loc="post">D</inf> 4.39 nM/N.D. ED: IC<inf loc="post">50</inf> (nM) 73<cross-ref id="crf0020" refid="tblfn0020">
                              <sup loc="post">d</sup>
                           </cross-ref>/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hLS9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.04 (LE), n.d. (ED) pmol/min/mg; 0.21 ml/h/kg (LE)<cross-ref id="crf0025" refid="tblfn0025">
                              <sup loc="post">e</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 20 μM, p = 100 μg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="3">
                           <cross-refs id="crfs0005" refid="bib0130 bib0165 bib0170 bib0190">[26,33,34,38]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">hIS9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.1 (LE), n.d. (ED) pmol/min/mg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 20 μM, p = 100 μg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">hPL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 12.2 h (LE), 1.35 h (ED); 2.41 ml/h/kg (LE)<cross-ref id="crf0030" refid="tblfn0025">
                              <sup loc="post">e</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 150 μM<cross-ref id="crf0035" refid="tblfn0030">
                              <sup loc="post">f</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">HSA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 69.4 h (LE), 7.14 h (ED)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p = 4% HSA solution</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Steroids</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IC<inf loc="post">50</inf> (nM) 3.0<cross-ref id="crf0040" refid="tblfn0020">
                              <sup loc="post">d</sup>
                           </cross-ref>/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hPL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1<cross-ref id="crf0045" refid="tblfn0035">
                              <sup loc="post">g</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 5 ng/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0050" refid="bib0190">[38]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1" role="rowhead rowgroup">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1" role="rowhead">Steroids</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">IC<inf loc="post">50</inf> (nM) 6.4/400</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hPL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 5 min</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 30 μg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">
                           <cross-ref id="crf0055" refid="bib0200">[40]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Human lung S9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">stable ≥2.5 h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 50 μg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>14</bold>, FP16CM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Steroids</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IC<inf loc="post">50</inf> (nM) 50.3/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">rPL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 29.4 min</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 30 μg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0060" refid="bib0220">[44]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Steroids</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ki<inf loc="post">ER</inf> (nM) 6.8/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">rLM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RHA<cross-ref id="crf0065" refid="tblfn0040">
                              <sup loc="post">h</sup>
                           </cross-ref> = 420</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 50 μM, p = 0.28 mg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0070" refid="bib0230">[46]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>17</bold>, sofpironium bromide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticholinergics</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>pKi</italic> M1–M4 8.99–9.45/6.43–8.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Rat blood rPL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">k = 7.2 min<sup loc="post">–1</sup>, t<inf loc="post">½</inf> = 96.6 min (k = 8.0 min<sup loc="post">–1</sup>, t<inf loc="post">½</inf> = 86.4 min)<cross-ref id="crf0075" refid="tblfn0050">
                              <sup loc="post">j</sup>
                           </cross-ref>; k = 15.8 min<sup loc="post">–1</sup>, t<inf loc="post">½</inf> = 44.0 min (k = 20.9 min<sup loc="post">–1</sup>, t<inf loc="post">½</inf> = 33.8 min)<cross-ref id="crf0080" refid="tblfn0050">
                              <sup loc="post">j</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 700 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0085" refid="bib0250">[50]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>18</bold>, crisaborole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDE4 inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Approved</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Oxidation and hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IC<inf loc="post">50</inf> PDE4 (nM) 490/N.D. (<bold>18</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0090" refid="bib0290">[58]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1" role="rowhead rowgroup">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1" role="rowhead">PDE4 inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">IC<inf loc="post">50 PDE4</inf> (nM) 47 /inhibition at 10<hsp sp="0.25"/></hsp>μM 5%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">mPL <italic>in vivo</italic> (mice) sc, po, iv</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.5% remaining after 1 h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">
                           <cross-ref id="crf0095" refid="bib0300">[60]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">
                           <italic>In vivo</italic> (mice) sc, po, iv</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 1.03 h (iv)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">100 mg/kg (sc, po), 25 mg/kg (iv)</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>21</bold>, lotamilast (E6005, RVT-501)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDE4 inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IC<inf loc="post">50</inf> (nM) 0.49–3.1/>100<cross-ref id="crf0100" refid="tblfn0045">
                              <sup loc="post">i</sup>
                           </cross-ref>; IC<inf loc="post">50</inf> PDE4 (nM) 2.8/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0105" refid="bib0310">[62]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>22</bold>, LEO-29102</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDE4 inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IC<inf loc="post">50</inf> PDE4 (nM) 5/3760</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hLM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL = 200 ml/min/kg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 0.5 μM, p = 0.5 mg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0110" refid="bib0330">[66]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">S1PR1 modulators</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hydrolysis and conjugation with UDPGA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IC<inf loc="post">50</inf> S1PR1 (nM) 25/10 (<bold>27</bold>)/0 (<bold>28</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hSS9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 7.3 min</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 0.5 μM, p = 0.3 mg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0115" refid="bib0360">[72]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6" role="rowhead rowgroup">
                           <bold>29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6" role="rowhead">TRPV1 modulators</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6">Hydrolysis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6">IC<inf loc="post">50</inf> TRPV1 (nM) 930/residual activity @ 1 μM 6.7%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hCE1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 27.2 min CL = 118 μl/min/mg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 50 μM, p = 0.2 mg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6">
                           <cross-ref id="crf0120" refid="bib0380">[76]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">hCE2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">½</inf> = 12.5 min CL = 256 μl/min/mg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 50 μM, p = 0.2 mg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">hLS9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Totally depleted after 1 h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 50 μM, P = 1 mg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">hPL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">82.0% remaining after 1 h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 100 μM</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">HaCaT homogenate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">98.6% remaining after 4 h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 25 μM, p = 0.4 mg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Keratinocyte homogenate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.6% remaining after 2 h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 50 μM, p = 0.4 mg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Fibroblast homogenate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.3% remaining after 2 h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 50 μM, p = 0.4 mg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">
                           <bold>30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Conjugation with UDPGA (putative soft spot)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IC<inf loc="post">50</inf> JAK1, 2, 3 (nM): 4.4, 6.3, 3.2/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hLM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL = 47 ml/min/kg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0125" refid="bib0400">[80]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1" role="rowhead rowgroup">
                           <bold>31</bold>, PF-06263276</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1" role="rowhead">JAK inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">Clinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">Conjugation with UDPGA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">IC<inf loc="post">50</inf> JAK1, 2, 3, and TYK2 (nM): 2.2, 23.1, 59.9, 29.7/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hLM (Phase I)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL = 101 μl/min/mg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1">
                           <cross-ref id="crf0130" refid="bib0415">[83]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">hLM supplied with UDPGA (Phase II)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL = 129 μl/min/mg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2" role="rowhead rowgroup">
                           <bold>32</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2" role="rowhead">Caspase 1 inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2">Hydrolysis (putative soft spot)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2">IC<inf loc="post">50</inf> THP1 (nM) 38/N.D.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">hSS9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL = 0.92 μl/min/mg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 1 μM, p = 2.3 mg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2">
                           <cross-ref id="crf0135" refid="bib0425">[85]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Normal human epidermal keratinocytes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL = 4.6 μl/min/10<sup loc="post">6</sup> cells</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 1 μM, 70 × 10<sup loc="post">3</sup> cells per well</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Human hepatocytes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL = 9.8 μl/min/10<sup loc="post">6</sup> cells</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">s = 1 μM, 0.5 × 10<sup loc="post">6</sup> cells/ml</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tblfn0005">
                  <ce:label>a</ce:label>
                  <ce:note-para id="npar0005" view="all">Abbreviations: hIS9, human intestinal S9; hLS9, human liver S9; hPL, human plasma; rPL, rat plasma; rLM, rat liver microsomes; mPL, mouse plasma; hLM, human liver microsomes; hSS9, human skin S9; hCE1–2, human carboxylesterase 1–2.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0010">
                  <ce:label>b</ce:label>
                  <ce:note-para id="npar0010" view="all">Phase of development represents the most advanced phase reached.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0015">
                  <ce:label>c</ce:label>
                  <ce:note-para id="npar0015" view="all">s = substrate concentration; p = enzyme protein concentration.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0020">
                  <ce:label>d</ce:label>
                  <ce:note-para id="npar0020" view="all">Inhibition of TNF-α production of LPS-stimulated whole blood cells.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0025">
                  <ce:label>e</ce:label>
                  <ce:note-para id="npar0025" view="all">Estimated clearance based on scaling factors.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0030">
                  <ce:label>f</ce:label>
                  <ce:note-para id="npar0030" view="all">Hydrolysis rate determined at increasing substrate concentration up to 150 μM.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0035">
                  <ce:label>g</ce:label>
                  <ce:note-para id="npar0035" view="all">Chromatographic peak area respect to the internal control.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0040">
                  <ce:label>h</ce:label>
                  <ce:note-para id="npar0040" view="all">RHA = relative hydrolytic activity compared to E16-1,2 = 100.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0045">
                  <ce:label>i</ce:label>
                  <ce:note-para id="npar0045" view="all">Suppression of cytokine production.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tblfn0050">
                  <ce:label>j</ce:label>
                  <ce:note-para id="npar0050" view="all">Data refer to compound <ce:bold>17</ce:bold> (<ce:italic>2R</ce:italic> enantiomer).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="doh0005">
               <ce:textfn>Review</ce:textfn>
               <ce:dochead id="doh0010">
                  <ce:textfn>Keynote</ce:textfn>
               </ce:dochead>
            </ce:dochead>
            <ce:title id="tit0005">Soft drugs for dermatological applications: recent trends</ce:title>
            <ce:author-group id="aug0005">
               <ce:author id="aut0005" biographyid="vt0005" author-id="S1359644619303356-b66952a69d03225dc7bf1854d8652a95">
                  <ce:given-name>Silvio</ce:given-name>
                  <ce:surname>Aprile</ce:surname>
               </ce:author>
               <ce:author id="aut0010" biographyid="vt0010" author-id="S1359644619303356-8e042cf2efa14d81e2850bcb642810c8">
                  <ce:given-name>Marta</ce:given-name>
                  <ce:surname>Serafini</ce:surname>
               </ce:author>
               <ce:author id="aut0015" biographyid="vt0015" author-id="S1359644619303356-250a2c96fd50653cd5c1316175d37c61">
                  <ce:given-name>Tracey</ce:given-name>
                  <ce:surname>Pirali</ce:surname>
                  <ce:cross-ref id="crf0140" refid="cor0005">⁎</ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff0005" affiliation-id="S1359644619303356-e3385b4cb701117cde957072c86e2a79">
                  <ce:textfn>Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>Università del Piemonte Orientale</sa:organization>
                     <sa:address-line>Largo Donegani 2</sa:address-line>
                     <sa:city>Novara</sa:city>
                     <sa:postal-code>28100</sa:postal-code>
                     <sa:country>Italy</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor0005">
                  <ce:label>⁎</ce:label>
                  <ce:text>
                     <ce:italic>Corresponding author</ce:italic>:</ce:text>
               </ce:correspondence>
            </ce:author-group>
            
            <ce:abstract id="abs0010" view="all" class="author"><ce:abstract-sec id="abst0010" view="all">
                  <ce:simple-para id="spar0045" view="all">A soft drug (SD) displays a metabolically labile spot and, after having exerted its activity in the site of action, undergoes a fast metabolism, leading to inactive metabolites. The SD approach has recently found widespread application in the dermatological field because it provides a means of localising the therapeutic effect in skin, while minimising systemic exposure. The literature is rapidly growing of successful examples of compounds targeting sphingosine-1-phosphate receptor 1 (S1PR1), transient receptor potential vanilloid 1 (TRPV1), Janus kinase (JAK), caspase 1, and histone deacetylase (HDAC), for the treatment of skin inflammatory, autoimmune, and oncological diseases. As a demonstration of the potential of this strategy, the SD approach recently led to the approval of crisaborole, a soft phosphodiesterase 4 (PDE4) inhibitor, for atopic dermatitis, while other agents are in clinical development.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract id="abs0015" class="teaser" view="all">
               <ce:section-title id="sect0010">Teaser</ce:section-title>
               <ce:abstract-sec id="abst0015" view="all">
                  <ce:simple-para id="spar0050" view="all">The soft drug approach is an effective strategy to define the action of topical dermatological drugs in the skin and obtain safer drugs.</ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0005" role="introduction" view="all">
                  <ce:section-title id="sect0015">Introduction</ce:section-title>
                  <ce:para id="par0025" view="all">Opposite to prodrugs and at times improperly named ‘antedrugs’, SDs are active compounds that display a metabolically labile designed-in spot, named the ‘soft spot’. This allows the drug to act in a particular compartment, but confers significant lability in other sites, thereby giving it organ specificity. Usually, these drugs are topically administered (e.g., eye, skin, intestines, nasal mucosa, or lung) and are rapidly inactivated when leaving the site of action, leading to no, or minute, systemic exposure and, therefore, increasing the therapeutic index. Over the years, the term ‘SD’ has been extended to compounds that are specifically designed to be vulnerable to rapid biotransformation into inactive metabolites. The anaesthesiology field, where a rapid offset is often desired, is particularly rich in short-acting drugs for systemic use <ce:cross-ref id="crf0145" refid="bib0005">[1]</ce:cross-ref>. There are no clear boundaries between a SD properly so called, that is a topical drug endowed with a controlled metabolic fate, and a systemic drug that is merely characterised by a short half-life; however, the former meaning is the one we mainly refer to in this review. In this narrow sense, SDs require the achievement of an adequate balance between the stability necessary to exert the desired biological activity in the site of action and the lability required to quench the compound in other sites, where undesired toxicities might occur. As discussed here, the key to achieving this is the exploitation of the existing differences in terms of the expression and activity of metabolizing enzymes between the site of action and the other districts.</ce:para>
                  <ce:para id="par0030" view="all">When the SD principle was first introduced during the late 1970s, accidental SDs were already in use <ce:cross-ref id="crf0150" refid="bib0010">[2]</ce:cross-ref>, including: etomidate (<ce:bold>1</ce:bold>, <ce:cross-ref id="crf0155" refid="fig0005">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig0005"/></ce:float-anchor>), a short-acting hypnotic agent; succinylcholine (<ce:bold>2</ce:bold>, <ce:cross-ref id="crf0160" refid="fig0005">Fig. 1</ce:cross-ref>); ester-type local anaesthetics, such as procaine (<ce:bold>3</ce:bold>, <ce:cross-ref id="crf0165" refid="fig0005">Fig. 1</ce:cross-ref>); and methylphenidate (<ce:bold>4</ce:bold>, <ce:cross-ref id="crf0170" refid="fig0005">Fig. 1</ce:cross-ref>), an amphetamine-related drug used for the treatment of attention-deficit-hyperactivity disorder. Soon after its formal introduction, the SD concept found application in the discovery of soft antimicrobial <ce:cross-ref id="crf0175" refid="bib0015">[3]</ce:cross-ref>, antitumor <ce:cross-ref id="crf0180" refid="bib0020">[4]</ce:cross-ref>, and anticholinergic <ce:cross-ref id="crf0185" refid="bib0025">[5]</ce:cross-ref> compounds, as described in the seminal papers published by Nicholas Bodor in 1980. Two years later, Henry Joung Lee coined the word ‘antedrug’, with the same concept as SDs, with reference to anti-inflammatory steroids devoid of pituitary-adrenal suppressive effect <ce:cross-ref id="crf0190" refid="bib0030">[6]</ce:cross-ref>. However, the expression of antedrugs has received little attention over the years and has been almost limited to the corticosteroid field.</ce:para>
                  <ce:para id="par0035" view="all">The initial successful exploitation of the SD concept by Bodor and Lee boosted the rational discovery of SDs that brought to the market other soft active principles, such as remifentanil (<ce:bold>5</ce:bold>, <ce:cross-ref id="crf0195" refid="fig0005">Fig. 1</ce:cross-ref>), a short-acting opioid, and esmolol (<ce:bold>6</ce:bold>, <ce:cross-ref id="crf0200" refid="fig0005">Fig. 1</ce:cross-ref>) and landiolol (<ce:bold>7</ce:bold>, <ce:cross-ref id="crf0205" refid="fig0005">Fig. 1</ce:cross-ref>), two ultrashort-acting beta-blockers, providing clear proof of the validity of the concept. A recent example is revefenacin (<ce:bold>8</ce:bold>, <ce:cross-ref id="crf0210" refid="fig0005">Fig. 1</ce:cross-ref>), a lung-selective muscarinic antagonist approved in 2018 in the USA for chronic obstructive pulmonary disease (COPD) <ce:cross-ref id="crf0215" refid="bib0035">[7]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0040" view="all">This topic and related examples of SDs in different therapeutic areas have been extensively reviewed elsewhere <ce:cross-refs id="crfs0010" refid="bib0040 bib0045 bib0050 bib0055 bib0060">[8–12]</ce:cross-refs>; therefore, we invite the reader to refer to these references for the general principles and properties of SDs, together with the different SD design methods (inactive metabolite-based SD, soft analogs, active metabolite-based SD, activated SD, and pro-SD). Here, we mainly focus on the application of the SD concept in the design and development of active principles for topical dermatological use, a setting to which the SD principle is ideally suited.</ce:para>
               </ce:section>
               <ce:section id="sec0010" view="all">
                  <ce:section-title id="sect0020">Softness criteria for topical dermatological drugs</ce:section-title>
                  <ce:para id="par0045" view="all">Most skin diseases that are potentially targeted by dermatological drugs are not severe, and it follows that, for therapies targeting skin, an ideal risk–benefit ratio would want not to consider systemic adverse effects. Topical administration is not always enough to guarantee the safety of the product, because the active principle might be absorbed through the skin, and, because of vascularization, reach the systemic circulation, with systemic adverse effects. Moreover, if the disease affects a large body surface area, the dose becomes higher and the risk of systemic effects more significant.</ce:para>
                  <ce:para id="par0050" view="all">Therefore, developing a SD can be a strategy to increase the therapeutic index. A topical dermatological drug is considered soft when it is stable or slowly degraded in the skin, while being promptly metabolised in other sites (mainly plasma and liver), therefore giving low systemic exposure. SDs for topical application should fulfil the following softness criteria: (i) low skin clearance to guarantee the therapeutic effect; (ii) high systemic clearance to avoid systemic adverse effects; (iii) avoidance of metabolism mediated by saturable pathways (e.g., oxidation) in favour of a metabolism carried out by prompt enzymes that have a different expression depending on organ or tissue (e.g., hydrolysis); and (iv) generation of inactive metabolites.</ce:para>
                  <ce:para id="par0055" view="all">To develop a topical dermatological SD with an ideal profile for clinical development, these softness criteria should be taken into account at an early stage of drug research and development (R&D) and experimentally investigated. This is not always the case and there is a rich body of literature that claims the softness of a topical dermatological drug without having confirmed the above requirements.</ce:para>
               </ce:section>
               <ce:section id="sec0015" view="all">
                  <ce:section-title id="sect0025">Considerations of metabolism in SD design</ce:section-title>
                  <ce:para id="par0060" view="all">Besides being a physical barrier, the skin is considered as an extrahepatic metabolizing organ. Although catalytic activities of metabolising enzymes are observed at relatively low levels per square centimetre of skin compared with other organs, skin-mediated metabolism becomes significant when considering the total skin surface area (1.5–2 m<ce:sup loc="post">2</ce:sup>, 15% of the body weight) <ce:cross-ref id="crf0220" refid="bib0065">[13]</ce:cross-ref>. Given that metabolism also impacts dermal absorption, metabolic activation (e.g., genotoxicity and sensitization induced by electrophilic reactive species), and skin irritation (e.g., conversion of esters into irritating alcohols, which are further oxidised to aldehydes and carboxylic acids) <ce:cross-ref id="crf0225" refid="bib0070">[14]</ce:cross-ref>, it is fundamental to understand which are the contributing enzymes in the skin, because they are different from the systemic metabolism.</ce:para>
                  <ce:para id="par0065" view="all">The approaches used to characterise cutaneous metabolism in recent years have made use of mRNA expression, proteomic profiling <ce:cross-ref id="crf0230" refid="bib0075">[15]</ce:cross-ref>, protein expression, and probe substrate activity <ce:cross-refs id="crfs0015" refid="bib0070 bib0080">[14,16]</ce:cross-refs>. Although the presence of mRNA, which encodes a specific metabolising enzyme, is an indication that the protein might be synthesised in the skin, this does not always correlate with the presence of the respective protein or with its functional activity and, therefore, a conclusive picture of the enzyme activity in the skin is still required. Nevertheless, it is well established that weak cytochromes P450 (CYP)-dependent monooxygenase, high transferase and esterase activities characterize the cutaneous setting, pointing to skin as a detoxifying, rather than an activating, organ <ce:cross-ref id="crf0235" refid="bib0065">[13]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0070" view="all">CYPs of the families 1–3, which are the major contributors to metabolism in the liver, show low activities in skin, with a decreasing order of potency in epidermis, dermis, and whole skin, indicating that their main localisation is in keratinocytes compared with other cell types <ce:cross-ref id="crf0240" refid="bib0080">[16]</ce:cross-ref>. Flavin-containing monooxygenases (FMOs) and cyclooxygenases (COXs), as well as other oxidoreductases, including xanthine oxidase and peroxidases, have been reported to be the non-CYP oxidoreductases of potential relevance for the skin <ce:cross-ref id="crf0245" refid="bib0070">[14]</ce:cross-ref>. The presence of aldehyde oxidase (AO) was only recently described, showing remarkable reaction rates <ce:cross-ref id="crf0250" refid="bib0085">[17]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0075" view="all">The most important phase II enzymes in skin are glutathione <ce:italic>S</ce:italic>-transferases (GSTs), UDP-glucuronosyltransferases (UGTs), <ce:italic>N</ce:italic>-acetyltransferases (NATs) <ce:cross-ref id="crf0255" refid="bib0090">[18]</ce:cross-ref>, and sulfotransferases (SULTs), the latter possibly leading to toxic metabolites (e.g., severe immune-mediated skin rash mediated by reactive benzyl sulfate) <ce:cross-ref id="crf0260" refid="bib0095">[19]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0080" view="all">Hydrolysing activity is reported to be relevant in skin <ce:cross-ref id="crf0265" refid="bib0065">[13]</ce:cross-ref>. Among the different hydrolases, esterases and/or amidases are known to contribute significantly to drug metabolism <ce:cross-ref id="crf0270" refid="bib0100">[20]</ce:cross-ref>. <ce:cross-ref id="crf0275" refid="fig0010">Figure 2</ce:cross-ref>
                     <ce:float-anchor refid="fig0010"/></ce:float-anchor> exemplifies the main compartments involved in the ester hydrolytic inactivation of topical SDs and their corresponding enzymes, together with the <ce:italic>in vitro</ce:italic> tools useful in the assessment of the softness degree.</ce:para>
                  <ce:para id="par0085" view="all">Carboxylesterases (CEs) catalyse the hydrolysis of esters, amides, thioesters, and carbamates. Human carboxylesterases (hCEs) are highly expressed at the cutaneous level <ce:cross-ref id="crf0280" refid="bib0065">[13]</ce:cross-ref>, but investigations into the expression of specific hCEs isoforms in skin remains controversial <ce:cross-ref id="crf0285" refid="bib0105">[21]</ce:cross-ref>. Indeed, both Zhu and Fu examined the expression of hCEs in HaCaT cells and detected hCE2 mRNA, whereas the hCE1 counterpart was undetectable <ce:cross-refs id="crfs0020" refid="bib0110 bib0115">[22,23]</ce:cross-refs>. By contrast, a more recent proteomic analysis of human skin highlighted the sole presence of hCE1 isoform <ce:cross-ref id="crf0290" refid="bib0075">[15]</ce:cross-ref>. CEs have a different propensity regarding the nature of substrates: it is well known that the preferential substrates for hCE1 are esters displaying a less hindered alcohol counterpart, whereas those for hCE2 are esters bearing a bulkier one <ce:cross-ref id="crf0295" refid="bib0120">[24]</ce:cross-ref>. Curiously, CEs are present in the plasma of most rodents, but are not found in primates <ce:cross-ref id="crf0300" refid="bib0125">[25]</ce:cross-ref>. By contrast, human plasma contains butyrylcholinesterase (BChE), paraoxonase (PON1), and acetylcholinesterase (AChE). Albumin (HSA) displays only poor esterase activity, but is so abundant (∼4%) <ce:cross-ref id="crf0305" refid="bib0130">[26]</ce:cross-ref> that it significantly contributes to ester hydrolysis <ce:cross-ref id="crf0310" refid="bib0135">[27]</ce:cross-ref>. Liver is characterised by the presence of CEs, with the hCE1 isoform more abundant than hCE2.</ce:para>
                  <ce:para id="par0090" view="all">Pathological conditions of the skin can affect the quality and extent of metabolism. Examples reviewed by Zhang <ce:italic>et al</ce:italic>. <ce:cross-ref id="crf0315" refid="bib0140">[28]</ce:cross-ref> show that significant induction of oxygenases and GSTs might occur in psoriasis, whereas the gene expression decrease for some CYPs. Surprisingly, polymorphisms of <ce:italic>CYP1A1</ce:italic> have also been shown to be associated with acne, although the relationship between xenobiotic metabolism and disease has not been extensively investigated <ce:cross-ref id="crf0320" refid="bib0140">[28]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0095" view="all">The human skin harbours >200 bacterial genera, with up to 10 million bacterial cells/cm<ce:sup loc="post">2</ce:sup>, a microbiome that is unique compared with other mammals <ce:cross-ref id="crf0325" refid="bib0145">[29]</ce:cross-ref>. The skin microbiome is capable of metabolising drugs and, therefore, might represent an important source for the metabolic activation and inactivation of xenobiotics <ce:cross-refs id="crfs0025" refid="bib0140 bib0150">[28,30]</ce:cross-refs>. This is even more true with regard to infected and/or diseased skin.</ce:para>
               </ce:section>
               <ce:section id="sec0020" view="all">
                  <ce:section-title id="sect0030">Tools to assess skin metabolism</ce:section-title>
                  <ce:para id="par0100" view="all">The most reliable experimental approach to assess drug metabolism in human skin is the use of viable <ce:italic>ex vivo</ce:italic> human skin samples. Indeed, topical application of the substrate on these models allows the evaluation of both skin permeation and metabolism. However, obtaining fresh <ce:italic>ex vivo</ce:italic> skin is far from straightforward and is often limited by the availability of donors.</ce:para>
                  <ce:para id="par0105" view="all">The most practical <ce:italic>in vitro</ce:italic> systems include the use of skin S9 homogenates derived from epidermis of abdominal skin, cultures of human primary keratinocytes and immortalized cells (e.g., immortalized human keratinocytes; HaCaT) and recombinant hCEs <ce:cross-ref id="crf0330" refid="bib0070">[14]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0110" view="all">Since 2013, when the use of animal testing was banned for testing novel cosmetic ingredients, innovative human 3D skin models have been developed as an alternative to animal experimentation. Examples include: (i) EpiDerm™, a 3D multilayered skin culture derived from human neonatal foreskin keratinocytes; (ii) Episkin™, a reconstructed human epidermis model derived from female adult keratinocytes from mammoplasty; (iii) reconstructed human epidermis (RHE), normal human keratinocytes derived from human neonatal foreskin; (iv) full-thickness models (FTMs), a dermal equivalent with human fibroblasts overlaid by a stratified, well-differentiated epidermis derived from normal human keratinocytes cultured on an inert polycarbonate filter (see <ce:cross-ref id="crf0335" refid="bib0065">[13]</ce:cross-ref> for histology and metabolising enzyme activity); and (v) a root sheath-derived reconstructed human epidermal (ORS-RHE) <ce:cross-refs id="crfs0030" refid="bib0070 bib0155">[14,31]</ce:cross-refs>. With respect to skin homogenates and keratinocytes cultures, reconstructed 3D models have a barrier that includes fibroblasts embedded in collagen, mimicking the dermis layer of natural skin. Moreover, the comparison of the metabolising activity of some 3D skin models with <ce:italic>ex vivo</ce:italic> human skin showed weak monooxygenase activity for both the systems, alongside high esterase and transferase activities <ce:cross-ref id="crf0340" refid="bib0065">[13]</ce:cross-ref>, thus suggesting the usefulness of these models for predicting SD stability in skin. Bätz <ce:italic>et al</ce:italic>. <ce:cross-ref id="crf0345" refid="bib0160">[32]</ce:cross-ref> reported that RHE and FTMs might be useful to quantitatively address the esterase activity of human skin in drug development, although increased activity compared with native human skin must be taken into account. Expression and activity of GSTs and NATs were found to be similar in both normal human skin and skin models <ce:cross-ref id="crf0350" refid="bib0065">[13]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0025" view="all">
                  <ce:section-title id="sect0035">Illustrative examples of dermatological SDs</ce:section-title>
                  <ce:para id="par0115" view="all">Over the years, the SD principle has been used to target a plethora of pathways involved in the pathogenesis of skin diseases; here, we present an overall review of examples, highlighting the rationale behind the SD design. In <ce:cross-ref id="crf0355" refid="tbl0005">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl0005"/></ce:float-anchor>, the most characterized compounds are reported, together with the biological activity in comparison with the metabolite. The models used for the assessment of the softness of the described compounds are detailed, when available, together with the clearance values and the experimental conditions used for their evaluation.</ce:para>
                  <ce:section id="sec0030" view="all">
                     <ce:section-title id="sect0040">Steroids</ce:section-title>
                     <ce:para id="par0120" view="all">Corticosteroids are among the most effective drugs on the market, but are burdened by severe adverse effects, even when applied topically. Therefore, it is not surprising that the SD principle has been extensively used in this field with the aim to improve the risk–benefit ratio.</ce:para>
                     <ce:para id="par0125" view="all">The development of soft corticosteroids represents the first rational application of the SD principle, leading to the successful development of both loteprednol etabonate (LE), <ce:cross-ref id="crf0360" refid="bib0170">[34]</ce:cross-ref> currently approved by US Food and Drug Administration (FDA) for the treatment of ocular inflammation, and etiprednol dicloacetate (ED) <ce:cross-ref id="crf0365" refid="bib0175">[35]</ce:cross-ref>, another soft corticosteroid that completed a Phase II clinical study but was not developed further <ce:cross-ref id="crf0370" refid="bib0180">[36]</ce:cross-ref>. These two examples are not dermatological drugs, but warrant a closer look because they bring to light important aspects for SD design.</ce:para>
                     <ce:para id="par0130" view="all">LE and ED were both designed starting from prednienic acid, an inactive metabolite of prednisolone. In particular, LE displays an ethyl carbonate ester and a chloromethyl ester (<ce:bold>9</ce:bold>, <ce:cross-ref id="crf0375" refid="fig0015">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig0015"/></ce:float-anchor>), whereas ED has a dichloromethyl ester and an ethyl ester at 17α- and 17β-positions (<ce:bold>10</ce:bold>, <ce:cross-ref id="crf0380" refid="fig0015">Fig. 3</ce:cross-ref>). Recently, it was reported that, although being stable in human liver and intestinal S9 fractions, LE in human plasma is slowly hydrolysed to a carboxyl metabolite at position 17β, whereas ED is metabolized, tenfold faster, to the hydroxylated derivative at position 17α (<ce:cross-ref id="crf0385" refid="tbl0005">Table 1</ce:cross-ref>) <ce:cross-ref id="crf0390" refid="bib0130">[26]</ce:cross-ref>, indicating that the dichloroacetyl function is cleaved more easily than the hindered 17β-ester.</ce:para>
                     <ce:para id="par0135" view="all">Hydrolysis assessment in the presence of selective inhibitors of plasma esterases (paraoxon and eserine) or with HSA showed that the main enzyme responsible for the hydrolysis of LE and ED is PON1, whereas HSA slightly hydrolysed ED but not LE. Given that PON1 is active in plasma, whereas hCEs are abundant in several tissues, LE and ED are stable in several districts (i.e., in the site of application), but they are promptly inactivated in plasma, a behaviour that is considered ideal for SDs. Furthermore, PON1 is associated with high-density lipoprotein (HDL), which does not diffuse from blood into tissues, guaranteeing the stable presence of LE at the administration site. By contrast, ED might be inactivated by HSA, which is instead present in the interstitial fluid of the administration site. In addition to the inactivation in plasma, the strong protein binding (˜98%) shown by LE and ED minimises their systemic adverse effects, confirming that plasma protein binding must be considered for the correct evaluation of hydrolytic stability data in plasma.</ce:para>
                     <ce:para id="par0140" view="all">Fluticasone propionate, an alleged soft steroid, does not undergo hydrolysis at the 7 β-fluoromethyl thioester because its clearance depends on the relatively slow CYP-450 catalysed metabolism <ce:cross-ref id="crf0395" refid="bib0185">[37]</ce:cross-ref>. In another study exploring analogs of ED <ce:cross-ref id="crf0400" refid="bib0190">[38]</ce:cross-ref>, the dichloroacetyl function was inserted at position 17α and the resulting compound (<ce:bold>11</ce:bold>, <ce:cross-ref id="crf0405" refid="fig0015">Fig. 3</ce:cross-ref>) was endowed with anti-inflammatory activity (IC<ce:inf loc="post">50</ce:inf> = 3.0 nM, <ce:cross-ref id="crf0410" refid="tbl0005">Table 1</ce:cross-ref>), measured as the ability to inhibit tumour necrosis factor (TNF)-α production in lipopolysaccharide (LPS)-stimulated blood cells. This activity decreased both in diluted human blood (1:5) and after overnight preincubation in human plasma, suggesting low hydrolytic stability in systemic circulation, even though the enzymes responsible for the deactivation are not identified <ce:cross-ref id="crf0415" refid="bib0190">[38]</ce:cross-ref>. Moreover, the anti-inflammatory activity of compound <ce:bold>11</ce:bold>, when intratracheally administered in ovalbumin-sensitised Brown Norway rat model, was superior to that of fluticasone.</ce:para>
                     <ce:para id="par0145" view="all">PONs are enzymes also responsible for the inactivation of different series of glucocorticoids described by Procopiou <ce:italic>et al</ce:italic>. <ce:cross-refs id="crfs0035" refid="bib0195 bib0200 bib0205">[39–41]</ce:cross-refs> in an extensive medicinal chemistry program aimed at discovering safer corticosteroids. The best candidate identified displayed a lactone moiety (<ce:bold>12</ce:bold>, <ce:cross-ref id="crf0420" refid="fig0015">Fig. 3</ce:cross-ref>) that is rapidly hydrolysed in plasma (<ce:cross-ref id="crf0425" refid="tbl0005">Table 1</ce:cross-ref>) to give an inactive metabolite (IC<ce:inf loc="post">50</ce:inf> = 400 nM versus IC<ce:inf loc="post">50</ce:inf> = 6.4 nM of <ce:bold>12</ce:bold>), while being stable in the lung S9 fraction for at least 2.5 h (<ce:cross-ref id="crf0430" refid="tbl0005">Table 1</ce:cross-ref>). It had a topical anti-inflammatory activity in the rat ear oedema model, showing attenuated adverse effects in the thymus involution test. These properties suggest such derivatives as excellent candidates for their topical use in asthma, but no further development has been reported.</ce:para>
                     <ce:para id="par0150" view="all">While the aforementioned examples refer to the treatment of ocular or respiratory diseases, fluocortyn butyl (<ce:bold>13</ce:bold>, <ce:cross-ref id="crf0435" refid="fig0015">Fig. 3</ce:cross-ref>) is a corticosteroid contained in marketed anti-inflammatory dermatological creams. It is the butyl ester of a C<ce:inf loc="post">21</ce:inf> carboxy steroid and was designed starting from fluocortolone-21-acid, an inactive metabolite of fluocortolone <ce:cross-ref id="crf0440" refid="bib0210">[42]</ce:cross-ref>. Fluocortyn butyl has the advantage of being hydrolysed into inactive species when systemically absorbed, but a full characterisation of its softness remains missing from the literature and its low intrinsic activity has so far limited its use.</ce:para>
                     <ce:para id="par0155" view="all">Over the years, several groups have attempted to further exploit the SD principle in the corticosteroid arena. Lee and collaborators have been active in the development of anti-inflammatory agents and their efforts in this direction have already been reviewed elsewhere <ce:cross-ref id="crf0445" refid="bib0215">[43]</ce:cross-ref>. Among the synthesised prednisolone derivatives displaying esters at various positions, FP16CM, a 9α-fluoroprednisolone with a methyl ester at C-16 (<ce:bold>14</ce:bold>, <ce:cross-ref id="crf0450" refid="fig0015">Fig. 3</ce:cross-ref>), was shown to be able, on the one hand, to reduce the inflammation in a croton oil-induced ear oedema model and, on the other hand, to limit undesired effects, such as body weight gain, thymus atrophy, or suppression of endogenous corticosterone levels. These features were attributable to the hydrolysis of FP16CM (t<ce:inf loc="post">½</ce:inf> = 29.4 min in rat plasma, <ce:cross-ref id="crf0455" refid="tbl0005">Table 1</ce:cross-ref>) into the inert acid metabolite. A hydrolysis study showed that a benzyl ester derivative (FP16CB), although endowed with a minor activity, was hydrolysed quickly (t<ce:inf loc="post">½</ce:inf> = 3.2 min) <ce:cross-ref id="crf0460" refid="bib0220">[44]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0160" view="all">Similar local anti-inflammatory activity and reduced systemic adverse effects were reported in 2014 for β-methylphenethylamine (MPEA), a cortienic acid derivative displaying both an amide and an ester in the chain at position 17β; however, only <ce:italic>in silico</ce:italic> predictions of metabolism and the biological activity of the putative main metabolite have been reported, thus limiting the significance of this research <ce:cross-ref id="crf0465" refid="bib0225">[45]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0165" view="all">Besides corticosteroids, the SD principle has been applied to other soft steroids, including estrogens, with the aim of developing agents able to perform an estrogenic stimulation confined to the area of administration <ce:cross-ref id="crf0470" refid="bib0230">[46]</ce:cross-ref>. Given that the skin contains estrogen receptors (ER), it represents a target organ for estrogen replacement therapy, and topical application of estrogens has been used to treat vaginal dyspareunia of menopause. Nevertheless, estrogen administration is associated with several risks, such as endometrial cancer, breast cancer, and stroke; therefore, the development of a soft topical agent would offer a means of improving safety, especially in women for whom systemic estrogens are contraindicated. A series of estradiol-16α-carboxylic acid esters were synthesized and evaluated for their ER affinity, for the biological activity in an <ce:italic>in vitro</ce:italic> estrogen-sensitive model, and for the relative rate of their enzymatic hydrolysis in rat hepatic microsomes <ce:cross-ref id="crf0475" refid="bib0230">[46]</ce:cross-ref>. The 2'-monofluorethyl ester of E<ce:inf loc="post">2</ce:inf>-16α-formate (<ce:bold>15</ce:bold>, <ce:cross-ref id="crf0480" refid="fig0015">Fig. 3</ce:cross-ref>) appeared the most promising compound, with a relative binding affinity (RBA) for human ERα of 16 and ERβ of 0.1, whereas the corresponding acid metabolite E16-1,0 was devoid of activity (RBA = 0). The high rate of hydrolytic cleavage (<ce:cross-ref id="crf0485" refid="tbl0005">Table 1</ce:cross-ref>) explains why, in the <ce:italic>in vivo</ce:italic> uterotrophic test for the evaluation of systemic estrogenic activity, the compound administered by subcutaneous injection was almost inactive, whereas, in the <ce:italic>in vivo</ce:italic> vaginal assay for the evaluation of local estrogenic activity, after topical application the compound exerted a significant estrogenic action. Two years later, the same authors reported carboxylic acid esters of estradiol at the α-, 11β- and 15α-positions. Among them, two compounds, the methyl and ethyl esters of estradiol-15α-formate, were shown to exert an improved local to systemic estrogenic profile <ce:cross-ref id="crf0490" refid="bib0235">[47]</ce:cross-ref>. Capitalising on the well-known beneficial effects of estrogens on cutaneous wound repair, 17α-substituted estradiol derivatives bearing an ester moiety were also investigated. One compound (<ce:bold>16</ce:bold>, <ce:cross-ref id="crf0495" refid="fig0015">Fig. 3</ce:cross-ref>), when injected subcutaneously, accelerated repair in a murine model of age-associated delayed wound healing at the same level as 17β-estradiol, without exerting systemic activity on ER <ce:cross-ref id="crf0500" refid="bib0240">[48]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0035" view="all">
                     <ce:section-title id="sect0045">Other soft dermatological agents</ce:section-title>
                     <ce:para id="par0170" view="all">Although the SD concept has primarily focused on the discovery of safer corticosteroids, over the past decades, the scope has broadened to involve other therapeutic classes (<ce:cross-ref id="crf0505" refid="tbl0005">Table 1</ce:cross-ref>).</ce:para>
                     <ce:section id="sec0040" view="all">
                        <ce:section-title id="sect0050">Anticholinergics</ce:section-title>
                        <ce:para id="par0175" view="all">Topical anticholinergics find application as mydriatic and/or cycoplegic agents, as well as antiperspirants, but might lead to systemic toxicity. The SD principle has been used since 1980 <ce:cross-refs id="crfs0040" refid="bib0025 bib0245">[5,49]</ce:cross-refs> starting from different lead compounds (i.e., acetylnorcholine and propantheline) and leading to the development of several series of soft anticholinergics, with the aim of separating the local therapeutic benefits from the off-site toxic effects. These attempts led to the recent clinical success of sofpironium bromide (BBI-4000, <ce:bold>17</ce:bold>, <ce:cross-ref id="crf0510" refid="fig0020">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig0020"/></ce:float-anchor>) for the treatment of hyperhidrosis, an unmet medical need. It was designed starting from glycopyrrolate, a quaternary ammonium compound with poor blood–brain barrier permeability and reduced central nervous system (CNS)-related adverse effects. In particular, one of the methyl groups on the quaternary ammonium site was replaced with an alkoxycarbonylethyl function and the resulting ester was found to be susceptible to extrahepatic metabolism (rat blood and plasma), consistent with its soft nature <ce:cross-refs id="crfs0045" refid="bib0250 bib0255">[50,51]</ce:cross-refs>. The fast hydrolysis to the less active zwitterionic metabolite resulted in a decrease of typical peripheral anticholinergic adverse effects (i.e., urinary retention and visual disturbances) <ce:cross-ref id="crf0515" refid="bib0260">[52]</ce:cross-ref>. For these reasons, sofpironium bromide has entered clinical trials and has completed Phase 2IIb and a Phase III trial in Japan, with a Phase III trial starting in the US <ce:cross-refs id="crfs0050" refid="bib0265 bib0270 bib0275">[53–55]</ce:cross-refs>.</ce:para>
                        <ce:para id="par0180" view="all">Interestingly, the same authors reported that the derivative displaying the methyl ester instead of the ethyl ester was not hydrolysed by CESs, ascribed to the fact that the quaternary ammonium structure impairs the transport into the luminal side of the endoplasmic reticulum, where CESs are located. By contrast, the hydrolysis is mediated by PON1. A difference, albeit small, in terms of hydrolytic stability is reported between rat (half-life: 9.8 min) and human (half-life: 16.9 min) plasma and this correlates with the different expression level of the enzyme in the two species.</ce:para>
                     </ce:section>
                     <ce:section id="sec0045" view="all">
                        <ce:section-title id="sect0055">PDE4 inhibitors</ce:section-title>
                        <ce:para id="par0185" view="all">PDE4 has emerged as a promising target for the treatment of various diseases associated with inflammation and, over the past decades, a plethora of inhibitors has been developed, leading to the approval of three drugs (i.e., roflumilast, apremilast, and crisaborole) in different clinical settings (airway diseases, psoriasis, and atopic dermatitis, respectively) <ce:cross-ref id="crf0520" refid="bib0280">[56]</ce:cross-ref>. However, significant efficacies of PDE4 inhibitors are often accompanied by serious adverse effects, especially on the gastrointestinal tract (nausea and vomiting). Roflumilast and apremilast were approved for oral use in 2010 and 2014, respectively, but both show non-negligible systemic impact, including psychiatric disorders. Topical delivery, such as inhalation and cutaneous application, would mitigate these adverse effects <ce:cross-ref id="crf0525" refid="bib0285">[57]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0190" view="all">This was exemplified by the successful development of crisaborole (AN2728, <ce:bold>18</ce:bold>, <ce:cross-ref id="crf0530" refid="fig0025">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig0025"/></ce:float-anchor>) <ce:cross-ref id="crf0535" refid="bib0290">[58]</ce:cross-ref>, a topical benzoxaborole approved in 2016 in the US for adults and children older than 2 years with atopic dermatitis (IC<ce:inf loc="post">50</ce:inf> = 490 nM). Its low molecular weight provides skin penetration, whereas the benzoxaborole geometry mimics the phosphate of cAMP. Clinical trials demonstrated that 2% ointment applied twice daily alleviated symptom severity, without causing gastrointestinal adverse effects <ce:cross-ref id="crf0540" refid="bib0295">[59]</ce:cross-ref>. Crisaborole penetrates the epidermis and dermis, and, when it reaches the systemic circulation, it is extensively metabolised into inactive metabolites, avoiding systemic exposure. The major metabolite is 5-(4-cyanophenoxy)-2-hydroxyl benzyl alcohol (AN7602, <ce:bold>19</ce:bold>, <ce:cross-ref id="crf0545" refid="fig0025">Fig. 5</ce:cross-ref>), which is formed by oxidative deboronation and subsequent hydrolysis. Given that the first metabolic step involves an oxidation mediated by CYP, crisaborole is not a canonical SD. AN7602 is further metabolised to produce several downstream metabolites, among which 5-(4-cyanophenoxy)-2-hydroxyl benzoic acid (produced by oxidation) and AN7602-sulfate (produced by sulfation) are major circulating components. CYP3A4 and 1A1/2 appear to have a major role in the formation of AN7602, together with CYP2B6 and 2E1, which also appear to contribute.</ce:para>
                        <ce:para id="par0195" view="all">Starting from crisaborole, the same authors developed a series of benzoxaborole derivatives where the soft spot was represented by the ester moiety. Among these derivatives, one compound (<ce:bold>20</ce:bold>, <ce:cross-ref id="crf0550" refid="fig0025">Fig. 5</ce:cross-ref>) displayed an IC<ce:inf loc="post">50</ce:inf> of 47 nM and a high tendency to be hydrolysed <ce:italic>in vitro</ce:italic> in mouse plasma and <ce:italic>in vivo</ce:italic> in mice to the corresponding and inactive acid metabolite (<ce:cross-ref id="crf0555" refid="tbl0005">Table 1</ce:cross-ref>). It inhibited ear oedema caused by phorbol esters after dosing at 1 mg/ear twice, suggesting a good skin stability and significant <ce:italic>in vivo</ce:italic> anti-inflammatory activity. It showed also a reduced emetic activity <ce:cross-ref id="crf0560" refid="bib0300">[60]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0200" view="all">Two PDE4 inhibitors are currently in Phase II for atopic dermatitis. The first is lotamilast (<ce:bold>21</ce:bold>, E6005, RVT-501, <ce:cross-ref id="crf0565" refid="fig0025">Fig. 5</ce:cross-ref>) <ce:cross-ref id="crf0570" refid="bib0305">[61]</ce:cross-ref>, which inhibits PDE-4 with an IC<ce:inf loc="post">50</ce:inf> of 2.8 nM. In mice models, topical application improved skin inflammation and pruritus without serious adverse effects <ce:cross-ref id="crf0575" refid="bib0310">[62]</ce:cross-ref>. Given that it displays a methyl ester, lotamilast is rapidly metabolized to the carboxylic acid (100 times weaker in suppressing cytokine production) and was characterised by a rapid clearance from the blood system and low distribution to the brain, as demonstrated by using <ce:sup loc="post">14</ce:sup>C-labeled lotamilast in mice <ce:cross-ref id="crf0580" refid="bib0310">[62]</ce:cross-ref>. Data collected in humans confirmed the preclinical data <ce:cross-refs id="crfs0055" refid="bib0315 bib0320">[63,64]</ce:cross-refs> and explained the very low levels of nausea and vomiting reported.</ce:para>
                        <ce:para id="par0205" view="all">The second candidate is LEO-29102 (<ce:bold>22</ce:bold>, <ce:cross-ref id="crf0585" refid="fig0025">Fig. 5</ce:cross-ref>) <ce:cross-ref id="crf0590" refid="bib0325">[65]</ce:cross-ref>, a compound displaying an IC<ce:inf loc="post">50</ce:inf> value of 5 nM. It was well tolerated in preclinical models with no emetic episodes or other prodromal signs up to 1 mg/kg, whereas the pharmacokinetics study in humans supported the SD concept, obtaining low systemic levels of active compound (C<ce:inf loc="post">max</ce:inf> 0.279–5.07 ng/ml and AUC<ce:inf loc="post">0-48h</ce:inf> 5.45–100 ng‧h/ml, according to the treated body surface area). The soft spot is represented by the amide, which, in human liver microsomes, undergoes fast hydrolysis (<ce:cross-ref id="crf0595" refid="tbl0005">Table 1</ce:cross-ref>), resulting in the corresponding carboxylic acid being the primary and inactive metabolite (IC<ce:inf loc="post">50</ce:inf>  = 4 μM) <ce:cross-ref id="crf0600" refid="bib0330">[66]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0210" view="all">HFP034 (<ce:bold>23</ce:bold>, <ce:cross-ref id="crf0605" refid="fig0025">Fig. 5</ce:cross-ref>) is an anthranilate derivative with an IC<ce:inf loc="post">50</ce:inf> value of 4.2 μM. In an imiquimod-induced mouse psoriasis model, its topical application ameliorated skin lesions and epidermal thickness. It is characterised by a butyl ester and the authors, using an <ce:italic>in vitro</ce:italic> Franz cell, demonstrated that the compound accumulates in the skin and is not delivered into systemic circulation. Although it is not described as a SD and no investigation on its metabolism has been reported, it is reasonable to assume that the compound is hydrolysed by esterases <ce:cross-ref id="crf0610" refid="bib0335">[67]</ce:cross-ref>.</ce:para>
                     </ce:section>
                     <ce:section id="sec0050" view="all">
                        <ce:section-title id="sect0060">S1PR1 modulators</ce:section-title>
                        <ce:para id="par0215" view="all">Besides PDE4 inhibitors, S1PR1 agonists have recently received widespread attention in the search for antipsoriasis treatments <ce:cross-ref id="crf0615" refid="bib0340">[68]</ce:cross-ref>. These compounds activate S1PR1 and lead to the internalization of the receptor, preventing the maturation and the migration of lymphocytes with an overall immunosuppressive effect. To date, fingolimod is the only S1PR1 agonist that has received FDA approval for the treatment of relapsing forms of multiple sclerosis, an indication extended also to the paediatric population in 2018. Ponesimod, another S1PR1 agonist, reached Phase II clinical trials for severe plaque psoriasis <ce:cross-refs id="crfs0060" refid="bib0345 bib0350">[69,70]</ce:cross-refs>, but has not proceeded further. Indeed, this class of molecules is affected by severe adverse effects (i.e., lymphopenia, bradycardia, and dyspnoea) that hamper its use in dermatological conditions. Starting from the structure of ponesimod, Bell <ce:italic>et al</ce:italic>. <ce:cross-ref id="crf0620" refid="bib0355">[71]</ce:cross-ref> reported a first series of ester analogues displaying good activity on S1PR1, with an IC<ce:inf loc="post">50</ce:inf> value of 2.5 nM for the most potent one. Compound <ce:bold>24</ce:bold> (<ce:cross-ref id="crf0625" refid="fig0030">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig0030"/></ce:float-anchor>) is hydrolysed to an inactive metabolite (IC<ce:inf loc="post">50</ce:inf> > 1 μM), but is relatively stable in human plasma, with a half-life of 180 minutes, compromising its soft nature. Further optimisation led to the identification of compound <ce:bold>25</ce:bold> (<ce:cross-ref id="crf0630" refid="fig0030">Fig. 6</ce:cross-ref>), with improved solubility and short half-life in both human plasma and S9 skin fraction (9 and 23 min, respectively, <ce:cross-ref id="crf0635" refid="tbl0005">Table 1</ce:cross-ref>). Unfortunately, the compound does not display significant activity on S1PR1 (IC<ce:inf loc="post">50</ce:inf> > 1 μM). In a second, more successful attempt, the authors described ponesimod analogues <ce:cross-ref id="crf0640" refid="bib0360">[72]</ce:cross-ref> in which the soft spot is provided by the phenol moiety. The most potent compound (<ce:bold>27</ce:bold>, <ce:cross-ref id="crf0645" refid="fig0030">Fig. 6</ce:cross-ref>) displays an IC<ce:inf loc="post">50</ce:inf> value of 10 nM on S1PR1 and intrinsic clearance in human liver microsomes and human liver hepatocytes of 2.8 ml/min/g and 31 ml/min/g, respectively. It is rapidly metabolised by Phase II enzymes in human hepatocytes to give <ce:bold>28</ce:bold> (<ce:cross-ref id="crf0650" refid="fig0030">Fig. 6</ce:cross-ref>). To avoid the chemical instability related to the phenol group, the hydroxyl moiety was esterified to give the methyl ester <ce:bold>26</ce:bold> (<ce:cross-ref id="crf0655" refid="fig0030">Fig. 6</ce:cross-ref>). The resulting molecule retains good potency on S1PR1 (IC<ce:inf loc="post">50</ce:inf> 25 nM) and is rapidly converted into <ce:bold>27</ce:bold> by the hydrolysing activity of skin S9 fraction esterases (<ce:cross-ref id="crf0660" refid="tbl0005">Table 1</ce:cross-ref>). Compound <ce:bold>26</ce:bold> represents a peculiar example of a SD that requires two steps for its inactivation: hydrolysis in skin and conjugation with glucuronic acid in liver.</ce:para>
                     </ce:section>
                     <ce:section id="sec0055" view="all">
                        <ce:section-title id="sect0065">TRPV1 modulators</ce:section-title>
                        <ce:para id="par0220" view="all">In 2018, the SD principle was applied to the structure of capsaicin, the pungent principle of hot chili peppers. Capsaicin acts as agonist of the TRPV1 channel, a calcium permeable ion channel mainly expressed in peripheral sensory neurons, where the receptor acts as a mediator of cutaneous pain, inflammation, and itch. Beside its role in the nervous system, the channel is involved in the pathogenesis of skin disorders, especially related to inflammation and pruritus. The therapeutic potential of capsaicin-containing creams and patches is provided by the ability of the molecule first to open the channel, leading to the most common adverse effect, a so-called ‘burning’ sensation, and then to mediate its desensitisation. Capsaicin can reside in human skin relatively unchanged for a long period of time, leading to frequent erythema reactions. Moreover, it has been reported that chronic and long-term topical applications can increase the risk of skin carcinogenesis if co-applied with a tumour promoter, such as sunlight <ce:cross-ref id="crf0665" refid="bib0365">[73]</ce:cross-ref>. Besides agonists, topical antagonists able to block the channel have been reported, but many clinical trials have been interrupted because of the risk of hyperthermia induction and promotion of skin cancer <ce:cross-refs id="crfs0065" refid="bib0370 bib0375">[74,75]</ce:cross-refs>. To circumvent these adverse effects, a class of capsaicin soft analogues has been developed in which an ester moiety is inserted in the lipophilic tail <ce:cross-refs id="crfs0070" refid="bib0380 bib0385 bib0390">[76–78]</ce:cross-refs>. This series included both agonists and antagonists, with a shift in the activity provided by the insertion of an iodine atom at 6-position of the aromatic core. Among these modulators, soft antagonists have been selected for further development, because no burning sensation was associated with topical administration. The most potent antagonist displays an IC<ce:inf loc="post">50</ce:inf> value on TRPV1 of 90 nM, but a poor metabolic instability (unmodified in human plasma and 50% cleared in liver S9). Therefore, the lead compound selected for the <ce:italic>in vivo</ce:italic> evaluation was <ce:bold>29</ce:bold> (<ce:cross-ref id="crf0670" refid="fig0030">Fig. 6</ce:cross-ref>), which is endowed with a good balance of potency (IC<ce:inf loc="post">50</ce:inf> 930 nM) and hydrolytic stability (<ce:cross-ref id="crf0675" refid="tbl0005">Table 1</ce:cross-ref>). According to the SD principle, the hydrolytic metabolite is inactive on TRPV1 (6.7% of activity at 1 μM). Compound <ce:bold>29</ce:bold> is able to suppress TRPV1-mediated nociceptor excitability and reduces <ce:italic>in vivo</ce:italic> both thermal hyperalgesia and histaminergic and non-histaminergic mediated pruritus. The toxicity of the molecule has also been evaluated: it does not affect either thermal nociception or body temperature and does not induce any conspicuous behavioural or motor deficits or other discomfort, such as burning sensation and pain.</ce:para>
                     </ce:section>
                     <ce:section id="sec0060" view="all">
                        <ce:section-title id="sect0070">JAK inhibitors</ce:section-title>
                        <ce:para id="par0225" view="all">JAKs, a family of four-member tyrosine kinases, represent a promising target in the field of inflammatory skin disorders, with several <ce:italic>in vivo</ce:italic> evidences of efficacy of JAK inhibitors in inflammatory disorders <ce:cross-ref id="crf0680" refid="bib0395">[79]</ce:cross-ref>. Two drugs, tofacitinib and ruxolitinib, have received FDA approval for the treatment of rheumatoid arthritis, and myelofibrosis and polycythaemia vera, respectively. Both drugs have been studied in several trials for the treatment of atopic dermatitis, psoriasis and alopecia aerata, but, because they are affected by important systemic adverse effects, such as immunosuppression and cytopenia, their use is incompatible with nonlife-threatening conditions.</ce:para>
                        <ce:para id="par0230" view="all">In an attempt to reduce these adverse effects, a fragment-based screening was performed in 2016 with the aim to discover novel pan-JAK inhibitors for topical use <ce:cross-ref id="crf0685" refid="bib0400">[80]</ce:cross-ref>. The identified hit fragment displays an IC<ce:inf loc="post">50</ce:inf> value of 30 μM on JAK1 and of 13 μM on JAK2. The optimisation of this fragment led to compound <ce:bold>30</ce:bold> (<ce:cross-ref id="crf0690" refid="fig0030">Fig. 6</ce:cross-ref>) with good potency on JAK1, JAK2, and JAK3 (IC<ce:inf loc="post">50</ce:inf>: 4.4 nM, 6.3 nM, and 3.2 nM, respectively). Unfortunately, neither the structure of the main metabolites nor their lack of activity was assessed. The selected compound bears a phenol moiety as a putative soft spot, which might undergo fast metabolism in the liver by conjugation with glucuronic acid, but no experimental data have been reported to support this hypothesis. Compound <ce:bold>30</ce:bold> displays an intrinsic clearance in human liver microsomes of 47 ml/min/kg (<ce:cross-ref id="crf0695" refid="tbl0005">Table 1</ce:cross-ref>), high enough to be considered a SD compared with the liver blood flow rate (20 m/min/kg). From a toxicological point of view, <ce:bold>30</ce:bold> inhibits also other off-target kinases and displays significant phototoxicity related to the presence of the indazole moiety, which can be photodegraded to reactive or toxic degradation products, therefore making the compound a poor candidate for further development.</ce:para>
                        <ce:para id="par0235" view="all">PF-06263276 (<ce:bold>31</ce:bold>, <ce:cross-ref id="crf0700" refid="fig0030">Fig. 6</ce:cross-ref>) is a pan-JAK inhibitor that advanced into clinical development <ce:cross-refs id="crfs0075" refid="bib0405 bib0410">[81,82]</ce:cross-refs> for psoriasis. A structure-based computational method allowed the discovery of a hit compound endowed with good potency on JAK1, -2, -3, and TYK2 (IC<ce:inf loc="post">50</ce:inf> 0.4, 2.2, 8.3, and 9.1 nM, respectively), but affected by poor aqueous solubility and modest turnover for both Phase I and II metabolism (CL<ce:inf loc="post">int</ce:inf> = 35 μl/min/mg hLM, and 49 μl/min/mg hLM, respectively supplied with uridine diphosphate glucuronic acid; UDPGA), despite the presence of a phenol moiety <ce:cross-ref id="crf0705" refid="bib0415">[83]</ce:cross-ref>. Further optimisation led to the identification of PF-06263276, which loses some potency on JAK1, -2, -3, and TYK2 (IC<ce:inf loc="post">50</ce:inf> 2.2, 23.1, 59.9, and 29.7 nM, respectively), but displays an improved turnover both for oxidative (hLM) and conjugative (hLM supplied with UDPGA) clearance (<ce:cross-ref id="crf0710" refid="tbl0005">Table 1</ce:cross-ref>). Moreover, the compound was selective for JAKs in a panel of 36 kinases and its crystalline solid form displayed excellent chemical and physical stability, allowing PF-06263276 to advance as a clinical candidate for both inhaled and topical delivery.</ce:para>
                     </ce:section>
                     <ce:section id="sec0065" view="all">
                        <ce:section-title id="sect0075">Caspase 1 inhibitors</ce:section-title>
                        <ce:para id="par0240" view="all">In the pathogenesis of acne <ce:cross-ref id="crf0715" refid="bib0420">[84]</ce:cross-ref>, many proinflammatory cytokines are involved and, in particular, interleukin (IL)-1β is abundant in human acne lesions. This cytokine normally exists in its inactive proform that, in the presence of inflammatory stimuli, is activated by the cleavage mediated by the aspartic cysteine protease caspase 1. A key binding element in caspase 1 inhibitors is a reactive warhead, which forms a covalent-reversible bond with the protein catalytic cysteine. Fournier <ce:italic>et al</ce:italic>. developed compounds in which an aspartyl aldehyde warhead is responsible for the activity, representing at the same time the soft spot because of its electrophilic nature <ce:cross-ref id="crf0720" refid="bib0425">[85]</ce:cross-ref>. The best candidate (<ce:bold>32</ce:bold>, <ce:cross-ref id="crf0725" refid="fig0030">Fig. 6</ce:cross-ref>, <ce:cross-ref id="crf0730" refid="tbl0005">Table 1</ce:cross-ref>) shows high skin flux (4.3 μM/cm<ce:sup loc="post">2</ce:sup>), good skin metabolic stability (CL<ce:inf loc="post">int</ce:inf> of 0.92 μl/min/mg of protein in skin S9 fraction and a CL<ce:inf loc="post">int</ce:inf> of 4.6 μl/min/10<ce:sup loc="post">6</ce:sup> cells in normal human epidermal keratinocytes) together with a good hepatic clearance (9.8 μl/min/10<ce:sup loc="post">6</ce:sup> cells in human hepatocytes) and low plasmatic exposure (1.3 nM). Nevertheless, no identification and evaluation of the resulting metabolites have been reported.</ce:para>
                     </ce:section>
                     <ce:section id="sec0070" view="all">
                        <ce:section-title id="sect0080">Androgen antagonists</ce:section-title>
                        <ce:para id="par0245" view="all">Acne is also associated with the overproduction of sebum by the sebaceous gland. In this regard, soft androgen receptor antagonists have been described, relying not on hydrolysis, but on the oxidation of the thioether (IC<ce:inf loc="post">50</ce:inf> = 43 nM) to the corresponding inactive sulfoxide (IC<ce:inf loc="post">50</ce:inf> > 10 000 nM). A few were able to moderately reduce wax (43–66%) and cholesterol (35–50%) esters when topically applied in hamsters, but the authors did not report either the evaluation of the metabolic stability of these derivatives, or the reduction of the associated systemic adverse effects <ce:cross-ref id="crf0735" refid="bib0430">[86]</ce:cross-ref>.</ce:para>
                     </ce:section>
                     <ce:section id="sec0075" view="all">
                        <ce:section-title id="sect0085">HDAC inhibitors</ce:section-title>
                        <ce:para id="par0250" view="all">The SD principle is also being exploited in the oncological field, in particular in cutaneous T cell lymphoma (CTLC), a heterogeneous cluster of cancers that affect T cells in skin. Among the flourishing therapeutic strategies, HDAC inhibition is particularly relevant given their epigenetic modifying properties <ce:cross-ref id="crf0740" refid="bib0435">[87]</ce:cross-ref>. Vorinostat is a hydroxamic acid approved in 2006 as oral agent, whereas romidepsin is a cyclic depsipeptide approved by the FDA in 2009 for parenteral use. Their systemic activity is often associated with fatigue, nausea, diarrhoea, thrombocytopenia, and cardiac toxicity. Thus, to improve the tolerability profiles, the soft hydroxamic acid remetinostat (SHP-141, <ce:bold>33</ce:bold>, <ce:cross-ref id="crf0745" refid="fig0030">Fig. 6</ce:cross-ref>) was developed and has completed a Phase II trial for the treatment of early-stage CTLC <ce:cross-refs id="crfs0080" refid="bib0440 bib0445 bib0450">[88–90]</ce:cross-refs>. After exerting its antitumoral activity in cutaneous lesions, it undergoes hydrolysis mediated by plasma BChE and PON1, to give methyl paraben and suberic acid hydroxamic acid as the main metabolites; however, further information is scarce and the methyl ester portion might be also hydrolysed <ce:cross-ref id="crf0750" refid="bib0455">[91]</ce:cross-ref>. Its topical formulation (SHAPE gel 0.5%), together with its hydrolytic lability, limit the adverse effects associated with systemic HDAC inhibition <ce:cross-refs id="crfs0085" refid="bib0460 bib0465">[92,93]</ce:cross-refs>. Preclinical examples of soft HDAC inhibitors include also a series of squaramides <ce:cross-ref id="crf0755" refid="bib0470">[94]</ce:cross-ref> characterised by high <ce:italic>in vitro</ce:italic> human hepatic clearance (29 μl/min/10<ce:sup loc="post">6</ce:sup> cells), although an evaluation of fulfilment of softness criteria has not been reported.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0080" role="discussion" view="all">
                  <ce:section-title id="sect0090">Discussion</ce:section-title>
                  <ce:para id="par0255" view="all">Typical dermatological SDs are compounds that are sufficiently stable in the skin but are readily inactivated once they leave the cutaneous microenvironment. Most of the SDs reported so far have been discovered by designing close steric and electronic analogues of known active drugs (the so-called ‘soft analogue approach’ <ce:cross-ref id="crf0760" refid="bib0060">[12]</ce:cross-ref>), with the aim of retaining the biological activity, while controlling and directing the metabolism towards the most desired way. Therefore, once the SD is designed, it is necessary to verify that the introduction of the soft spot in the molecule retains the potency and that the main metabolites formed are inactive, an essential precondition for further SD development.</ce:para>
                  <ce:para id="par0260" view="all">Most SDs are based on hydrolytic transformations, especially esterase-mediated reactions. Indeed, although drug clearance mainly relies on oxidative reactions mediated by CYP family, oxidation is rarely exploited in the design of SDs because it is generally slow, easily saturable, and often leads to reactive and toxic metabolites. The only examples in this review where softness relies on oxidation are crisaborole, <ce:bold>18</ce:bold>, where oxidative deborination occurs, and an androgen receptor antagonist where the thioether is oxidized to sulfoxide.</ce:para>
                  <ce:para id="par0265" view="all">By contrast, hydrolysis reactions usually lead to inactive metabolites that are promptly conjugated and/or excreted. The loss of activity is usually attributed to a decrease in affinity to the target and/or to a reduced membrane permeability, both related to a decrease in lipophilicity. Moreover, hydrolysis reactions are fast and not easily saturable transformations. Compared with oxidations, which suffer from interspecies and interindividual variability, as well as inhibition and induction, hydrolysis is less prone to this variability, with few exceptions that include PON1, an enzyme affected by polymorphisms. Last, esterases are expressed in different levels, depending on the organ or tissue, and these differences could be exploited in the design of SDs that are stable in skin, but unstable in other settings.</ce:para>
                  <ce:para id="par0270" view="all">Hence, it is not surprising that, in the examples discussed in this review, the insertion of a hydrolytically labile spot, an ester, or an amide, is the most pursued strategy in dermatological SDs design. Two exceptions are represented by SDs bearing a phenol that is conjugated with glucuronic acid (<ce:bold>30</ce:bold> and <ce:bold>31</ce:bold>), together with compound <ce:bold>26</ce:bold>, where the methyl ester is first hydrolysed to the corresponding phenol (<ce:bold>27</ce:bold>) in the skin and then conjugated with glucuronic acid (<ce:bold>28</ce:bold>) in the liver <ce:cross-refs id="crfs0090" refid="bib0360 bib0400 bib0415">[72,80,83]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0275" view="all">SD stability in skin needs to be assessed and could be evaluated in a plethora of skin models, from skin S9 homogenates, to keratinocyte and fibroblast homogenates and cultures, alongside recombinant hCEs. 3D skin models have been so far overlooked, despite representing a reliable model for the assessment of both metabolism and permeation through the cutaneous barrier. By contrast, nonhuman models are not always predictive of the hydrolytic capacity of human skin, with primates being the best predictive model, although minipig skin subcellular fractions also appear a reliable model for quantitative human epidermal esterase activity <ce:cross-ref id="crf0765" refid="bib0475">[95]</ce:cross-ref>. Generally speaking, rodents have a higher hydrolytic activity compared with humans, whereas dogs have a slower hydrolytic activity. Therefore, in the preclinical development of a novel SD, undesirable ultrarapid hydrolysis in rodents does not necessary translate into a poor compound for human use.</ce:para>
                  <ce:para id="par0280" view="all">Once it has exerted its therapeutic effects in skin, an ideal SD should undergo extensive metabolic inactivation before excretion, ideally first in bloodstream and then in other sites devoted to drug metabolism. Hence, SD inactivation in plasma and liver models needs to be investigated. Human plasma is endowed with high hydrolase activity mainly because of the presence of PON1 and BChE hydrolases. Given that they are almost absent in skin, PON1 and BChE are good candidates as bioconverting enzymes that can lead to successful SDs with effective local action and minimized systemic adverse effects, as exemplified by LE (<ce:bold>9</ce:bold>), ED (<ce:bold>10</ce:bold>), compound <ce:bold>12</ce:bold> 
                     <ce:cross-refs id="crfs0095" refid="bib0130 bib0200">[26,40]</ce:cross-refs>, and sofpironium bromide <ce:bold>17</ce:bold> 
                     <ce:cross-ref id="crf0770" refid="bib0260">[52]</ce:cross-ref>. SD clearance in blood should be preferably assessed avoiding the use of plasma from mice and rats. Indeed, CEs are present in the plasma of most rodents but are not found in primates <ce:cross-ref id="crf0775" refid="bib0125">[25]</ce:cross-ref>. Besides differences in the expression level, phenotyping experiments with selective probes of plasma hydrolases (e.g., EDTA, an inhibitor of PON1, or eserine, a selective inhibitor of BChE) and incubations with HSA <ce:cross-ref id="crf0780" refid="bib0130">[26]</ce:cross-ref> enable researchers to predict the resistance of SDs at the site of action. Indeed, PON1, which is associated with lipoproteins, is not able to reach the administration site, in contrast to HSA, which is present in the interstitial fluid and in the administration site. Finally, plasma protein binding must be considered for the correct evaluation of the hydrolytic stability data in plasma. Indeed, if low levels of unbound drug in plasma occur, the hydrolysis rate of drugs in plasma should be considered to be faster compared with their hydrolysis in buffer, where drugs are totally unbound.</ce:para>
                  <ce:para id="par0285" view="all">Structure–activity and structure–metabolism relationships (SARs and SMRs) should be exploited to reach a compromise between potency and softness degree and to identify the best candidate for <ce:italic>in vivo</ce:italic> proof of concept. The efforts in this direction could be reduced by relying on the information that is already available in the literature. For instance, it is well known that hydrolysis of linear alkanoates increases with the elongation of the chain, whereas branching and unsaturation generally decrease esterases activity <ce:cross-refs id="crfs0100" refid="bib0100 bib0380">[20,76]</ce:cross-refs>. Benzyl esters are labile toward hydrolases, <ce:cross-refs id="crfs0105" refid="bib0220 bib0480">[44,96]</ce:cross-refs> suggesting that they could be exploited for the design of very short-acting SDs. However, the differences in hydrolysis rate depend not only on the nature of the ester group, but also on its position. Altering both the nature and position of the ester moiety offers a means of modulating the hydrolytic stability profile of the compounds and covering a range of different potential indications for which local administration is applicable.</ce:para>
                  <ce:para id="par0290" view="all">The experimental activities in this direction can be minimised using <ce:italic>in silico</ce:italic> techniques: virtual libraries of possible soft analogues could be generated and ranked according to the steric ad electronic analogy to the active lead compound and predicted hydrolytic lability <ce:cross-refs id="crfs0110" refid="bib0045 bib0485 bib0490 bib0495">[9,97–99]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0295" view="all">Obviously, softness cannot be defined based solely on <ce:italic>in vitro</ce:italic> experiments, although <ce:italic>in vivo</ce:italic> data alone are insufficient for a fruitful drug discovery program not based on chance. Nevertheless, the literature is rich in examples where no efforts of SAR and SMR are undertaken and the SD is directly tested in an animal model to verify the local therapeutic activity and the absence of systemic adverse effects.</ce:para>
               </ce:section>
               <ce:section id="sec0085" view="all">
                  <ce:section-title id="sect0095">Concluding remarks</ce:section-title>
                  <ce:para id="par0300" view="all">The challenge goal in SD design is not to accelerate metabolism, but rather to avoid it in the site where the action is desired (e.g., the skin), while maintaining it in the other compartments. The SD approach represents an effective tool in the medicinal chemists’ toolbox, especially when safe, topically applied dermatological drugs need to be developed, but it is not necessarily straightforward. It is not a mere incorporation of an ester into an existing scaffold, and it requires the rigorous and experimental evaluation of a set of requirements. This is elegantly exemplified, for example, by recent work by Boland and coworkers <ce:cross-ref id="crf0785" refid="bib0500">[100]</ce:cross-ref> that describes soft ROCK inhibitors. Despite being beyond the scope of this review, because it does not target the skin, this study represents an excellent example of medicinal chemistry efforts made to develop a promising SD.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0005" view="all">
               <ce:section-title id="sect0100">Acknowledgments</ce:section-title>
               <ce:para id="par0305" view="all">M.S. is supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, rif. 22568) fellowship for Italy. S.A. holds a temporary research fellow (Bando Formazione CRT-id393) supported by Università degli Studi del Piemonte Orientale, which is gratefully acknowledged. T.P. gratefully acknowledges <ce:grant-sponsor id="gs0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Ministero dell'Istruzione, dell'Università e della Ricerca</ce:grant-sponsor> (MIUR) for financial support (PRIN 2017 N° <ce:grant-number refid="gs0005">2017WJZ9W9</ce:grant-number>). The authors thank both Giorgio Grosa and Armando Genazzani for proofreading the manuscript.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl0005" view="all">
               <ce:section-title id="sect0105">References</ce:section-title>
               <ce:bibliography-sec id="bibs0005" view="all">
                  <ce:bib-reference id="bib0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Egan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Is anesthesiology going soft? Trends in fragile pharmacology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anesthesiology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>229</sb:first-page>
                              <sb:last-page>230</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel approaches for the design of membrane transport properties of drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>E.B.</ce:given-name>
                                    <ce:surname>Roche</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Design of Biopharmaceutical Properties through Prodrugs and Analogs</sb:maintitle>
                              </sb:title>
                              <sb:date>1977</sb:date>
                              <sb:publisher>
                                 <sb:name>Academy of Pharmaceutical Sciences</sb:name>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>98</sb:first-page>
                              <sb:last-page>135</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>1980</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>469</sb:first-page>
                              <sb:last-page>474</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Kaminski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Soft drugs. 2. Soft alkylating compounds as potential antitumor agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>1980</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>566</sb:first-page>
                              <sb:last-page>569</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Soft drugs. 3. A new class of anticholinergic agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>1980</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>474</sb:first-page>
                              <sb:last-page>480</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Soliman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-inflammatory steroids without pituitary adrenal suppression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>215</sb:volume-nr>
                              </sb:series>
                              <sb:date>1982</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>989</sb:first-page>
                              <sb:last-page>991</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.A.</ce:given-name>
                                 <ce:surname>Heo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revefenacin: first global approval</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>91</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Soft drug design: general principles and recent applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Res. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>58</sb:first-page>
                              <sb:last-page>101</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>123</sb:first-page>
                              <sb:last-page>132</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in the design and development of soft drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmazie</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>403</sb:first-page>
                              <sb:last-page>413</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Retrometabolism-based drug design and targeting</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>D.J.</ce:given-name>
                                    <ce:surname>Abraham</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Burger’s Medicinal Chemistry and Drug Discovery</sb:maintitle>
                              </sb:title>
                              <sb:date>2003</sb:date>
                              <sb:publisher>
                                 <sb:name>Wiley</sb:name>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                              <sb:last-page>608</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Retrometabolic Drug Design and Targeting</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2012</sb:date>
                              <sb:publisher>
                                 <sb:name>Wiley</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Eilstein</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparison of xenobiotic metabolizing enzyme activities in ex vivo human skin and reconstructed human skin models from SkinEthic</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1681</sb:first-page>
                              <sb:last-page>1694</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Oesch</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>92</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2411</sb:first-page>
                              <sb:last-page>2456</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>van Eijl</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:article-number>e41721</sb:article-number>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Oesch</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Xenobiotic-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2135</sb:first-page>
                              <sb:last-page>2190</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Manevski</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aldehyde oxidase activity in fresh human skin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Metab. Dispos.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2049</sb:first-page>
                              <sb:last-page>2057</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Götz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Xenobiotic metabolism capacities of human skin in comparison with a 3D-epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: phase II enzymes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>364</sb:first-page>
                              <sb:last-page>369</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>12-OH-nevirapine sulfate, for<ce:italic>Med.</ce:italic> in the skin, is responsible for nevirapine-induced skin rash</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Res. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>817</sb:first-page>
                              <sb:last-page>827</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Testa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2003</sb:date>
                              <sb:publisher>
                                 <sb:name>Wiley-VCH</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Svensson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biotransformation of drugs in human skin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Metab. Dispos.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>247</sb:first-page>
                              <sb:last-page>253</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biotransformation capacity of carboxylesterase in skin and keratinocytes for the penta-ethyl ester prodrug of DTPA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Metab. Dispos.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1313</sb:first-page>
                              <sb:last-page>1318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.G.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stereoselective characteristics and mechanisms of epidermal carboxylesterase metabolism observed in HaCaT keratinocytes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biol. Pharm. Bull.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>532</sb:first-page>
                              <sb:last-page>536</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hosokawa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>412</sb:first-page>
                              <sb:last-page>431</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.G.</ce:given-name>
                                 <ce:surname>Bahar</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Species difference of esterase expression and hydrolase activity in plasma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharm. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3979</sb:first-page>
                              <sb:last-page>3988</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Samir</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of esterase involved in the metabolism of two corticosteroid soft drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>127</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>82</sb:first-page>
                              <sb:last-page>89</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1673</sb:first-page>
                              <sb:last-page>1684</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cutaneous metabolism in transdermal drug delivery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Metab.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>227</sb:first-page>
                              <sb:last-page>235</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Ross</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comprehensive skin microbiome analysis reveals the uniqueness of human skin and evidence for phylosymbiosis within the class Mammalia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>E5786</sb:first-page>
                              <sb:last-page>E5795</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sowada</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Degradation of benzoapyrene by bacterial isolates from human skin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FEMS Microbiol. Ecol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>129</sb:first-page>
                              <sb:last-page>139</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bacqueville</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of xenobiotic metabolizing enzymes of a reconstructed human epidermal model from adult hair follicles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Toxicol. Appl. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>329</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>190</sb:first-page>
                              <sb:last-page>201</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Bätz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Esterase activity in excised and reconstructed human skin-biotransformation of prednicarbate and the model dye fluorescein diacetate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Pharm. Biopharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>84</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>374</sb:first-page>
                              <sb:last-page>835</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Steroids</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>193</sb:first-page>
                              <sb:last-page>208</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Druzgala</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Steroid Biochem. Mol Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>1991</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>149</sb:first-page>
                              <sb:last-page>154</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Kurucz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>307</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>83</sb:first-page>
                              <sb:last-page>92</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multicenter Trial For Patients With Acute Crohn’s Disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2013</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT00035503</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0005" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.T.H.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>125</sb:volume-nr>
                              </sb:series>
                              <sb:date>1989</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1662</sb:first-page>
                              <sb:last-page>1665</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharm. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1745</sb:first-page>
                              <sb:last-page>1753</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Biggadike</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                              <sb:last-page>21</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Procopiou</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel glucocorticoid antedrugs possessing a 17β-(γ-lactone) ring</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>602</sb:first-page>
                              <sb:last-page>612</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Angell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel glucocorticoid antedrugs possessing a 21-(γ-lactone) ring</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Soc. Perkin. Trans.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2002</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>831</sb:first-page>
                              <sb:last-page>839</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Laurent</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New biologically active pregnan-21-oic acid esters</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Steroid Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>1975</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>185</sb:first-page>
                              <sb:last-page>192</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Omar</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and pharmacology of anti-inflammatory steroidal antedrugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5131</sb:first-page>
                              <sb:last-page>5145</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0220">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.-K.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and pharmacological evaluations of new steroidal anti-inflammatory antedrugs: 9α-Fluoro-11β,17α,21-trihydroxy-3,20-dioxo-pregna-1,4-diene-16α-carboxylate (FP16CM) and its derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Steroids</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>83</sb:first-page>
                              <sb:last-page>89</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Dobričić</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and local anti-inflammatory activity of 17β-carboxamide derivatives of glucocorticoids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>347</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>786</sb:first-page>
                              <sb:last-page>797</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Labaree</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Estradiol-16α-carboxylic acid esters as locally active estrogens</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1802</sb:first-page>
                              <sb:last-page>1814</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Labaree</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of B-, C- and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1886</sb:first-page>
                              <sb:last-page>1904</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Brufani</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel locally active estrogens accelerate cutaneous wound healing. A preliminary study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>543</sb:first-page>
                              <sb:last-page>556</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0245">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref0245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1681</sb:first-page>
                              <sb:last-page>1689</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0250">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref0250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and pharmacological effects of new, N‐substituted soft anticholinergics based on glycopyrrolate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharm. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1427</sb:first-page>
                              <sb:last-page>1435</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0255">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref0255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2035</sb:first-page>
                              <sb:last-page>2044</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0260">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref0260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Samir</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of major esterase involved in hydrolysis of soft anticholinergic (2R3’R-SGM) designed from glycopyrrolate in human and rat tissues</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharm. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2791</sb:first-page>
                              <sb:last-page>2797</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0265">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref0265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT03627468</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0010" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0270">
                     <ce:label>54</ce:label>
                     <sb:reference id="sbref0270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL–301) (Cardigan I)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT038362879</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0015" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0275">
                     <ce:label>55</ce:label>
                     <sb:reference id="sbref0275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL–302) (Cardigan II)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT03948646</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0020" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0280">
                     <ce:label>56</ce:label>
                     <sb:reference id="sbref0280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>21</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0285">
                     <ce:label>57</ce:label>
                     <sb:reference id="sbref0285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAMA Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>155</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>585</sb:first-page>
                              <sb:last-page>593</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0290">
                     <ce:label>58</ce:label>
                     <sb:reference id="sbref0290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Akama</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2129</sb:first-page>
                              <sb:last-page>2132</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0295">
                     <ce:label>59</ce:label>
                     <sb:reference id="sbref0295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.T.</ce:given-name>
                                 <ce:surname>Zane</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunotherapy</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>853</sb:first-page>
                              <sb:last-page>866</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0300">
                     <ce:label>60</ce:label>
                     <sb:reference id="sbref0300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.-K.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatological anti-inflammatory application</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2270</sb:first-page>
                              <sb:last-page>2274</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0305">
                     <ce:label>61</ce:label>
                     <sb:reference id="sbref0305">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A Phase 2 Study of E6005 in Patients With Atopic Dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2018</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT01461941</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0025" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0310">
                     <ce:label>62</ce:label>
                     <sb:reference id="sbref0310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>346</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>105</sb:first-page>
                              <sb:last-page>112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0315">
                     <ce:label>63</ce:label>
                     <sb:reference id="sbref0315">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ohba</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Dermatolog. Treat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>241</sb:first-page>
                              <sb:last-page>246</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0320">
                     <ce:label>64</ce:label>
                     <sb:reference id="sbref0320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Furue</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Topical E6005/RVT-501, a novel phosphodiesterases 4 inhibitor, for the treatment of atopic dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1403</sb:first-page>
                              <sb:last-page>1408</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0325">
                     <ce:label>65</ce:label>
                     <sb:reference id="sbref0325">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>LEO 29102 Cream in the Treatment of Atopic Dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2013</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT01037881</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0030" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0330">
                     <ce:label>66</ce:label>
                     <sb:reference id="sbref0330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Felding</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]2,3-dimehoxyphenoxy}-<ce:italic>N</ce:italic>-propylacetamide (LEO29102), a soft-drug inhibitor of phosphodiesterase for topical treatment of atopic dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5893</sb:first-page>
                              <sb:last-page>5903</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0335">
                     <ce:label>67</ce:label>
                     <sb:reference id="sbref0335">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FASEB J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>13</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0340">
                     <ce:label>68</ce:label>
                     <sb:reference id="sbref0340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Borodzicz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of epidermal sphingolipids in dermatologic diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lipids Health Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13</sb:first-page>
                              <sb:last-page>21</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0345">
                     <ce:label>69</ce:label>
                     <sb:reference id="sbref0345">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2013</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT01208090</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0035" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0350">
                     <ce:label>70</ce:label>
                     <sb:reference id="sbref0350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ACT-128800 in Psoriasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT00852670</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0040" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0355">
                     <ce:label>71</ce:label>
                     <sb:reference id="sbref0355">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3255</sb:first-page>
                              <sb:last-page>3259</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0360">
                     <ce:label>72</ce:label>
                     <sb:reference id="sbref0360">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of soft-drug topical tool modulators of sphingosine-1-phosphate receptor 1 (S1PR1)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>341</sb:first-page>
                              <sb:last-page>347</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0365">
                     <ce:label>73</ce:label>
                     <sb:reference id="sbref0365">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Bode</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The two faces of capsaicin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2809</sb:first-page>
                              <sb:last-page>2814</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0370">
                     <ce:label>74</ce:label>
                     <sb:reference id="sbref0370">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.R.</ce:given-name>
                                 <ce:surname>Gavva</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pain</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>136</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>202</sb:first-page>
                              <sb:last-page>210</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0375">
                     <ce:label>75</ce:label>
                     <sb:reference id="sbref0375">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Biol. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>143</sb:first-page>
                              <sb:last-page>162</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0380">
                     <ce:label>76</ce:label>
                     <sb:reference id="sbref0380">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Serafini</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting transient receptor potential vanilloid 1 (TRPV1) channel softly: the discovery of Passerini adducts as a topical treatment for inflammatory skin disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4436</sb:first-page>
                              <sb:last-page>4455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0385">
                     <ce:label>77</ce:label>
                     <sb:reference id="sbref0385">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pirali</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug discovery for soft drugs on TRPV1 and TRPM8 channels using the Passerini reaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Methods Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1987</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>207</sb:first-page>
                              <sb:last-page>221</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0390">
                     <ce:label>78</ce:label>
                     <sb:reference id="sbref0390">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Kargbo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TRPV1 modulators for the treatment of pain and inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>143</sb:first-page>
                              <sb:last-page>144</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0395">
                     <ce:label>79</ce:label>
                     <sb:reference id="sbref0395">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Damsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>King</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK inhibitors in dermatology: the promise of a new drug class</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. Acad. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>736</sb:first-page>
                              <sb:last-page>744</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0400">
                     <ce:label>80</ce:label>
                     <sb:reference id="sbref0400">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ritzén</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based discovery of 6-arylindazole JAK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>641</sb:first-page>
                              <sb:last-page>646</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0405">
                     <ce:label>81</ce:label>
                     <sb:reference id="sbref0405">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF–06263276 In Healthy Subjects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2014</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT01981681</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0045" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0410">
                     <ce:label>82</ce:label>
                     <sb:reference id="sbref0410">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2016</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT02193815</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0050" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0415">
                     <ce:label>83</ce:label>
                     <sb:reference id="sbref0415">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of a pan-janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>767</sb:first-page>
                              <sb:last-page>786</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0420">
                     <ce:label>84</ce:label>
                     <sb:reference id="sbref0420">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>MacKenzie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The potential for caspases in drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Drug Discov. Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>568</sb:first-page>
                              <sb:last-page>576</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0425">
                     <ce:label>85</ce:label>
                     <sb:reference id="sbref0425">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Fournier</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rational drug design of topically administered caspase 1 inhibitors for the treatment of inflammatory acne</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4030</sb:first-page>
                              <sb:last-page>4051</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0430">
                     <ce:label>86</ce:label>
                     <sb:reference id="sbref0430">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mitchell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1310</sb:first-page>
                              <sb:last-page>1313</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0435">
                     <ce:label>87</ce:label>
                     <sb:reference id="sbref0435">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Med. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>424</sb:first-page>
                              <sb:last-page>442</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0440">
                     <ce:label>88</ce:label>
                     <sb:reference id="sbref0440">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2016</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT02213861</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0055" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0445">
                     <ce:label>89</ce:label>
                     <sb:reference id="sbref0445">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT03180528</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0060" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0450">
                     <ce:label>90</ce:label>
                     <sb:reference id="sbref0450">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>ClinicalTrials.gov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Identifier: NCT03875859</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0065" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/ClinicalTrials.gov" xlink:type="simple">ClinicalTrials.gov</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0455">
                     <ce:label>91</ce:label>
                     <sb:reference id="sbref0455">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bradner</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A soft-drug histone deacetylase inhibitor for cutaneous T-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>800</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0460">
                     <ce:label>92</ce:label>
                     <sb:reference id="sbref0460">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase 1b study in cutaneous T-cell lymphoma (CTLC) with the novel topically applied skin-restricted histone deacetylase inhibitor (HDAC-i) SHP–141</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8525</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0465">
                     <ce:label>93</ce:label>
                     <sb:reference id="sbref0465">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Duvic</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase 2 randomized study of SHAPE gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: interim results</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7562</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0470">
                     <ce:label>94</ce:label>
                     <sb:reference id="sbref0470">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Fournier</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2985</sb:first-page>
                              <sb:last-page>2992</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0475">
                     <ce:label>95</ce:label>
                     <sb:reference id="sbref0475">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Prusakiewicz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparison of skin esterase activities from different species</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1517</sb:first-page>
                              <sb:last-page>1524</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0480">
                     <ce:label>96</ce:label>
                     <sb:reference id="sbref0480">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pirali</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a potent phosphoinositide 3-kinase pan inhibitor displaying a strategic carboxylic acid group and development of its prodrugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1542</sb:first-page>
                              <sb:last-page>1554</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0485">
                     <ce:label>97</ce:label>
                     <sb:reference id="sbref0485">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of computational techniques in retrometabolic drug design strategies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>J.</ce:given-name>
                                    <ce:surname>Leszczynski</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Computational Molecular Biology</sb:maintitle>
                              </sb:title>
                              <sb:date>1999</sb:date>
                              <sb:publisher>
                                 <sb:name>Elsevier</sb:name>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>569</sb:first-page>
                              <sb:last-page>618</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0490">
                     <ce:label>98</ce:label>
                     <sb:reference id="sbref0490">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bodor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based estimation of enzymatic hydrolysis rates and its application in computer-aided retrometabolic drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmazie</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>210</sb:first-page>
                              <sb:last-page>217</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0495">
                     <ce:label>99</ce:label>
                     <sb:reference id="sbref0495">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Buchwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Computer-aided retrometabolic drug design: soft drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>923</sb:first-page>
                              <sb:last-page>933</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0500">
                     <ce:label>100</ce:label>
                     <sb:reference id="sbref0500">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Boland</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4309</sb:first-page>
                              <sb:last-page>4324</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
            <ce:biography id="vt0005" view="all">
               <ce:link xlink:href="pii:S1359644619303356/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx1" xlink:type="simple"/></ce:link>
               <ce:simple-para id="spar0055" view="all">
                  <ce:bold>Silvio Aprile</ce:bold> received his PhD in the science of bioactive compounds from the Università del Piemonte Orientale (Novara, Italy) in 2008, where he is currently postdoctoral research fellow. His research focuses on the optimization of absorption, distribution, metabolism, and excretion (ADME) properties of new chemical entities, with an emphasis on drug metabolism. Current fields of interest include the ADME characterization of NAMPT inhibitors in oncology and TRPV1 soft modulators as anti-inflammatory agents.</ce:simple-para>
            </ce:biography>
            <ce:biography id="vt0010" view="all">
               <ce:link xlink:href="pii:S1359644619303356/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx2" xlink:type="simple"/></ce:link>
               <ce:simple-para id="spar0060" view="all">
                  <ce:bold>Marta Serafini</ce:bold> received her MSc in pharmaceutical chemistry and technology in 2015 from the Università del Piemonte Orientale. She is currently a PhD student in chemistry and biology in the Department of Pharmaceutical Sciences in Novara under the supervision of Tracey Pirali. In 2019, she received a fellowship supported by Fondazione AIRC. Her fields of interest focus on the discovery of novel IDO inhibitors for cancer immunotherapy and TRPV1 soft modulators.</ce:simple-para>
            </ce:biography>
            <ce:biography id="vt0015" view="all">
               <ce:link xlink:href="pii:S1359644619303356/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx3" xlink:type="simple"/></ce:link>
               <ce:simple-para id="spar0065" view="all">
                  <ce:bold>Tracey Pirali</ce:bold> received her PhD in the science of bioactive compounds from the Università del Piemonte Orientale in 2007. She spent sabbatical leaves in Jieping Zhu’s lab at the CNRS in Gif-sur-Yvette (Paris) and at the School of Chemistry in Edinburgh (UK) with Michael Greaney. In 2012, she received the Farmindustria Prize from the Italian Chemical Society. In 2016, she co-founded the start-up ChemICare. Currently, she is associate professor of medicinal chemistry at the Università del Piemonte Orientale and her main research interests are in the design and synthesis of bioactive compounds, with a special emphasis on TRPV1 and SOCE modulators.</ce:simple-para>
            </ce:biography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>